



HAL
open science

Seroprevalence and SARS-CoV-2 invasion in general populations: A scoping review over the first year of the pandemic

Clémentine Metzger, Taylor Leroy, Agathe Bochnakian, Helene Jeulin, Anne Gégout-Petit, K. Legrand, Evelyne Schvoerer, Francis Guillemin

► To cite this version:

Clémentine Metzger, Taylor Leroy, Agathe Bochnakian, Helene Jeulin, Anne Gégout-Petit, et al.. Seroprevalence and SARS-CoV-2 invasion in general populations: A scoping review over the first year of the pandemic. PLoS ONE, 2023, 18 (4), pp.e0269104. 10.1371/journal.pone.0269104. hal-04409991

HAL Id: hal-04409991

<https://hal.science/hal-04409991>

Submitted on 22 Jan 2024

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution 4.0 International License

RESEARCH ARTICLE

Seroprevalence and SARS-CoV-2 invasion in general populations: A scoping review over the first year of the pandemic

Clémentine Metzger¹, Taylor Leroy¹, Agathe Bochnakian¹, Hélène Jeulin^{2,3}, Anne Gegout-Petit⁴, Karine Legrand¹, Evelyne Schvoerer^{2,3}, Francis Guillemin^{1*}

1 CHRU -Nancy, INSERM, Université de Lorraine, CIC Epidémiologie clinique, F-54000, Nancy, France, **2** Université de Lorraine, CNRS, LCPME, F-54000, Nancy, France, **3** Laboratoire de Virologie, CHRU de Nancy Brabois, F-54500, Nancy, France, **4** Université de Lorraine, CNRS, Inria, IECL, F-54000, Nancy, France

* francis.guillemin@chru-nancy.fr



OPEN ACCESS

Citation: Metzger C, Leroy T, Bochnakian A, Jeulin H, Gegout-Petit A, Legrand K, et al. (2023) Seroprevalence and SARS-CoV-2 invasion in general populations: A scoping review over the first year of the pandemic. PLoS ONE 18(4): e0269104. <https://doi.org/10.1371/journal.pone.0269104>

Editor: Chandrabose Selvaraj, Alagappa University, INDIA

Received: October 25, 2021

Accepted: May 13, 2022

Published: April 19, 2023

Peer Review History: PLOS recognizes the benefits of transparency in the peer review process; therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. The editorial history of this article is available here: <https://doi.org/10.1371/journal.pone.0269104>

Copyright: © 2023 Metzger et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: Toutes les données pertinentes se trouvent dans le manuscrit et ses fichiers d'informations à l'appui All relevant data is

Abstract

Since the beginning of the COVID-19 pandemic, counting infected people has underestimated asymptomatic cases. This literature scoping review assessed the seroprevalence progression in general populations worldwide over the first year of the pandemic. Seroprevalence studies were searched in PubMed, Web of Science and medRxiv databases up to early April 2021. Inclusion criteria were a general population of all ages or blood donors as a proxy. All articles were screened for the title and abstract by two readers, and data were extracted from selected articles. Discrepancies were resolved with a third reader. From 139 articles (including 6 reviews), the seroprevalence estimated in 41 countries ranged from 0 to 69%, with a heterogeneous increase over time and continents, unevenly distributed among countries (differences up to 69%) and sometimes among regions within a country (up to 10%). The seroprevalence of asymptomatic cases ranged from 0% to 31.5%. Seropositivity risk factors included low income, low education, low smoking frequency, deprived area residency, high number of children, densely populated centres, and presence of a case in a household. This review of seroprevalence studies over the first year of the pandemic documented the progression of this virus across the world in time and space and the risk factors that influenced its spread.

Introduction

The coronavirus disease outbreak, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was first reported in Wuhan in December 2019 and spread rapidly to other parts of the world. On April 30, 2021, COVID-19 accounted for 150,000,000 confirmed cases worldwide, more than 3,000,000 deaths and about 87,000,000 recoveries, representing the deadliest pandemic in decades [1]. To contain the spread of the virus, daily counts of laboratory-confirmed cases and deaths have been published in real time.

in the manuscript and its [supporting information files](#).

Funding: The study was funded by Metropole du Grand (https://www.grandnancy.eu/accueil/). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing interests: The authors have declared that no competing interests exist.

The emergence of this new virus has resulted in an important early warning plan, and the WHO has tried to understand its modes of transmission, severity, characteristics and risk factors for infection. This alert plan was targeted to manage this epidemic, which became a pandemic barely 2 months after its appearance [2]. The plan includes refining case referrals, reinforcing surveillance, and defining the main epidemiological characteristics of COVID-19 to help understand the spread, severity, spectrum of the disease and impact on the community and to provide guidance on the application of countermeasures such as case isolation and contact tracing. Daily counts of confirmed COVID-19 cases and deaths alone provide incomplete information on the relative abundance of epidemiological compartments of a susceptible infected, recovered or deceased population. Therefore, the WHO has recommended repeatedly carrying out seroprevalence surveys in multiple geographical settings [2].

Several serological surveys of SARS-CoV-2 have been performed, and others are ongoing since the beginning of the COVID-19 pandemic, finding variable seroprevalence in different countries, sometimes even among regions of the same country [3,4].

The purpose of this literature scoping review was to summarise and map the results of the seroprevalence studies according to the time since the onset of the pandemic and geographical region and to identify risk factors.

Methods

We performed a literature review of seroprevalence studies conducted in different populations since the onset of the pandemic up to April 10, 2021, searching PubMed, Web of Science and medRxiv databases. We searched references of citations for reviews, which allowed for additional references to be added.

Eligibility

We included original articles and reviews written in English language that reported data for the general population living in a defined geographical area. We considered a general population as a population-based sample, a described general population sample, or the inclusion of men and women of unselected categories of all ages in the population, preferably (but not exclusively) obtained by a random sampling technique from a large population (survey or database). We also included blood donors as a proxy for the general population. We excluded studies of health care workers, people attending a clinic or a hospital, a professional branch (industry, factory, farmers, university) and a particular population (students, nursing home) as well as modelling studies.

Search strategy

The strategy consisted of searching PubMed and medRxiv with “(Covid OR SARS-CoV-2) AND seroprevalence” and Web of Science with “covid AND seroprevalence”. Articles were selected by reading titles and abstracts. All article titles were first read by two readers (CM, AB), then by a third one (FG or TL), which allowed for discussion in case of discrepancies after abstract reading to obtain consensus. Full-article reading allowed for the final selection of relevant studies and data extraction.

Data extraction

Data extraction was conducted by three authors who used a standardized form. The data collected, when available, were location; selection criteria; type of population; sample size and method; seroprevalence; serological test and type of Ig antibody tested; time period of the

study; presence and type of symptoms; risk factors such as age, sex, ethnicity and origin; local medical resources; and social class.

Results

Study characteristics

The search strategy yielded 742 articles from PubMed, 281 from Web of Science and 1141 from medRxiv. The selection of relevant articles, after removal of duplicates, yielded 139 articles, including 6 reviews and meta-analysis [5–10], published from January 1, 2020 to April 10, 2021 (Fig 1). Article references described in this section refer to those in Table 1. Of the 133 original studies, 31 were of blood donors. In 64 studies, the sample included all ages; in 40, it included people ≥ 18 years old; and a few studied people $<$ age 18 years ($n = 17$) or 10 years ($n = 12$). Some studies identified co-morbidities or asymptomatic cases. The samples ranged from 194 to 10,294,728 participants.




Fig 1. PRISMA flowchart.

<https://doi.org/10.1371/journal.pone.0269104.g001>

Table 1. Characteristics of country, methods, population of seroprevalence of included studies.

NUMBER	1.	2.	3.	4.
REFERENCE	Appa A, Takahashi S, Rodriguez-Barraquer I, Chamie G, Sawyer A, Duarte E, et al. Universal PCR and antibody testing demonstrate little to no transmission of SARS-CoV-2 in a rural community. MedRxiv Prepr Serv Health Sci. 17 août 2020;	Angulo FJ, Finelli L, Swerdlow DL. Estimation of US SARS-CoV-2 Infections, Symptomatic Infections, Hospitalizations, and Deaths Using Seroprevalence Surveys. JAMA Netw Open. 4 janv 2021;4(1):e2033706	Arnold CRK, Srinivasan S, Herzog CM, Gontu A, Bharti N, Small M, et al. SARS-CoV-2 Seroprevalence in a University Community: A Longitudinal Study of the Impact of Student Return to Campus on Infection Risk Among Community Members. MedRxiv Prepr Serv Health Sci. 19 févr 2021;	Alessi D, Borré S, Barale A, Isabella A, Milano F, Rossi MA, et al. [Seroprevalence of anti-SARS-CoV-2 IgG/IgM antibodies in Borgosesia (Piedmont Region, Northern Italy) population: a surveillance strategy in post-lockdown period?]. Epidemiol Prev. déc 2020;44(5–6 Suppl 2):200-6.
LOCATION/COUNTRY	Bolinas, California, the county of Marin	United States	Pennsylvanie	Borgosesia, (Piemonte region, northern Italy)
SELECTION CRITERIA	Men and women, 4 years old and over	Men and women, all ages	Men and women, 18 years old and over	Men and women, 18 years old and over, average age 55 Greater participation of women (54.4%) People with higher education (37.3%) People without specific previous symptoms (95.1%)
TYPE OF POPULATIONS	County residents and workers	General population	Residents living in a Centre at the University of Pennsylvania	General population
SAMPLE SIZE	1,891	April (n = 16,596), May (n = 14,291), June (n = 14,159), July (n = 12,367) August (n = 38,355)	345	4,987
SAMPLING METHOD	Random sampling	Random sampling	Random sampling	Random sampling
SEROPREVALENCE	0.16%	14.3% positive cases in the mid November	Of 345 community participants, 19 (5–5%) were positive for IgG SARS-CoV-2 antibodies. Of the 625 student participants who returned to campus for classes in the fall 195 (31–2%) were positive for SARS-CoV-2 antibodies. Twenty-eight (8–1%) of the community participants returned a positive IgG antibody result IgG antibody result by 9 December	245 individuals tested positive for IgM or IgG, and the estimated prevalence was 4.9%. 209 out of 245 subjects who were positive on the rapid test underwent RT-PCR and this resulted in the isolation of 24 positive subjects
STUDY PERIOD	April-2020	November-2020	August-December 2020	May-2020
RISK FACTORS		The most densely populated centres were the most affected by COVID-19		
SYMPTOMS	fever, cough, muscle aches, severe fatigue, difficulty breathing, diarrhea, loss of smell and/or taste			Mild symptoms
NUMBER	5.	6.	7.	8.
REFERENCE	Aziz NA, Corman VM, Echterhoff AKC, Richter A, Schmandke A, Schmidt ML, et al. Seroprevalence and correlates of SARS-CoV-2 neutralizing antibodies: Results from a population-based study in Bonn, Germany [Internet]. 2020 Aug [cited 2022 Jan 17] p. 2020.08.24.20181206. Available from: https://www.medrxiv.org/content/10.1101/2020.08.24.20181206v1	Babu GR, Sundaresan R, Athreya S, Akhtar J, Pandey PK, Maroor PS, et al. The burden of active infection and anti-SARS-CoV-2 IgG antibodies in the general population: Results from a statewide survey in Karnataka, India [Internet]. medRxiv; 2020 [cited 2022 Jan 26]. p. 2020.12.04.20243949. Available from: https://www.medrxiv.org/content/10.1101/2020.12.04.20243949v1	Bajema KL, Wiegand RE, Cuffe K, Patel SV, Iachan R, Lim T, et al. Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020. JAMA Intern Med. 1 avr 2021;181(4):450-60.	Batista KBC, Caseiro MM, Barros CR, Martins LC, Chioro A, Araújo ESA de, et al. COVID-19 Seroprevalence in Baixada Santista Metropolitan Area–Brazil [Internet]. medRxiv; 2020 [cited 2022 Feb 2]. p. 2020.08.28.20184010. Available from: https://www.medrxiv.org/content/10.1101/2020.08.28.20184010v1

(Continued)

Table 1. (Continued)

NUMBER	1.	2.	3.	4.
LOCATION/ COUNTRY	City of Bonn, Germany	Karnataka, India	United States (50 states)	Baixada Santista Metropolitan Area, Brazil
SELECTION CRITERIA	People (women and men) aged 30 years and above who lived in Bonn, Germany The population was the population enrolled in the Rhineland study	Men and women, 18 years old and over	Men and women, all ages	Men and women, all ages
TYPE OF POPULATIONS	An ongoing community based prospective cohort study (adults in general population)	General population	General population	Probabilistic population-based sample
SAMPLE SIZE	4,771	16,416	204,287	2,342
SAMPLING METHOD	Based on geographical areas and volunteers Random sampling	Based on geographical areas (hospitals from districts) Random sampling	Random sampling	Randomized in each city and street selection based on data drawn from the 2010 Brazilian census Stratified by age, gender and living conditions
SEROPREVALENCE	0.97% (95% CI: 0.72–1.30) by ELISA. 0.36% (95% CI: 0.21–0.61) by PRNT	IgG: 16.4% (95% CI: 15.1–17.7)	Jurisdictional seroprevalence over 4 collection periods collection periods ranged from less than 1% to 23%. In 42 of the 49 jurisdictions with sufficient samples to estimate to estimate seroprevalence in all periods, less than 10% of individuals had detectable SARS-CoV-2 antibodies	1.4% at a 95%CI level (0.93–1.93)
STUDY PERIOD	24. Avril-30. June 2020	3. September-16. September 2020	September-2020	February-2020
RISK FACTORS		Regions, age		
SYMPTOMS	A recent history of reduced taste or smell, fever, chills/hot flashes, pain while breathing, pain in arms/legs, as well as muscle pain and weakness			
NUMBER	9.	10.	11.	12.
REFERENCE	Biggs HM, Harris JB, Breakwell L, Dahlgren FS, Abedi GR, Szablewski CM, et al. Estimated Community Seroprevalence of SARS-CoV-2 Antibodies—Two Georgia Counties, April 28–May 3, 2020. MMWR Morb Mortal Wkly Rep. 24 juill 2020;69(29):965-70.	Bobrovitz N., Krishan Arora R., Cao C., Boucher E., Liu M., Donnici C., et al. “Global seroprevalence of SARS-CoV-2 antibodies: A systematic review and meta-analysis. Plos One. 26 Dec 2021, 16(6):e0252617.	Bogogiannidou Z, Vontas A, Dadouli K, Kyritsi MA, Soteriades S, Nikoulis DJ, et al. Repeated leftover serosurvey of SARS-CoV-2 IgG antibodies, Greece, March and April 2020. Euro Surveill Bull Eur Sur Mal Transm Eur Commun Dis Bull. août 2020;25(31).	Borges LP, Martins AF, de Melo MS, de Oliveira MGB, Neto JM de R, Dósea MB, et al. Seroprevalence of SARS-CoV-2 IgM and IgG antibodies in an asymptomatic population in Sergipe, Brazil. Rev Panam Salud Publica Pan Am J Public Health. 2020;44:e108.
LOCATION/ COUNTRY	DeKalb and Fulton counties, in the metropolitan Atlanta area Atlanta, Georgia	Worldwide	Greece	The state of Sergipe, Brazil.
SELECTION CRITERIA	Men and women, all ages	Men and women, all ages	Men and women, 18 years old and over	Men (48.2%), Women (51.8%), all ages (average 39.76 years)
TYPE OF POPULATIONS	General population of these two counties	General population	General population	Asymptomatic general population
SAMPLE SIZE	696 and 394 households	9,329,185, in 968 serosurveys from 605 reports	6,586	3,046
SAMPLING METHOD	Two-stage clustering was used to randomly select 30 census blocks in each county	Several techniques	Geographical stratification, sampling on global units All of which gives a representative sample	Stratified sample

(Continued)

Table 1. (Continued)

NUMBER	1.	2.	3.	4.
SEROPREVALENCE	19 positive cases of 696 i.e. 2.7% of the total	Between 0.6% in South East Asia and 59% Sub-Saharan Africa: 5.01% South Asia: 2.84% Central Europe, Eastern Europe, and Central Asia: 2.83% Latin America and Caribbean: 2.71% Southeast Asia, East Asia, and Oceania: 0.18%	0.36% 24 positive cases out of 6,586 samples	347 tested positive for IgM, 218 tested positive for IgG Women over 40 years of age had the highest prevalence for IgM
STUDY PERIOD	April-May 2020	September 2019- December 2020	March-April 2020	May-2020
RISK FACTORS	The most densely populated centres were the most affected by COVID-19	Job type, patient's COVID 19 contact, deprived area, location, ethnicity/race, age		
SYMPTOMS	Cough or shortness of breath, fever, loss of taste or smell		Mild symptoms	Asymptomatic cases
NUMBER	13.	14.	15.	16.
REFERENCE	Carrat F, Lamballerie X de, Rahib D, Blanché H, Lapidus N, Artaud F, et al. Seroprevalence of SARS-CoV-2 among adults in three regions of France following the lockdown and associated risk factors: a multicohort study [Internet]. 2020 Sep [cited 2022 Jan 20] p. 2020.09.16.20195693. Available from: https://www.medrxiv.org/content/10.1101/2020.09.16.20195693v1	Cerino P, Coppola A, Volzone P, Pizzolante A, Pierri B, Atripaldi L, et al. Seroprevalence of SARS-CoV-2-specific antibodies in the town of Ariano Irpino (Avellino, Campania, Italy): a population-based study . Future Sci Oa.:FSO673.	Chen X, Chen Z, Azman AS, Deng X, Sun R, Zhao Z, et al. Serological evidence of human infection with SARS-CoV-2: a systematic review and meta-analysis . Lancet Glob Health. 8 mars 2021;	Coyle PV, Chemaitelly H, Kacem MABH, Molawi NHAA, Kahlout RAE, Gilliani I, et al. SARS-CoV-2 seroprevalence in the urban population of Qatar: An analysis of antibody testing on a sample of 112,941 individuals [Internet]. 2021 Jan [cited 2022 Jan 20] p. 2021.01.05.21249247. Available from: https://www.medrxiv.org/content/10.1101/2021.01.05.21249247v1
LOCATION/COUNTRY	France	Ariano Irpino, Italy	European region, American region Western Pacific region	Qatar
SELECTION CRITERIA	Participants in a survey on COVID-19 from an existing consortium of three general adult population cohorts living in the Ile-de-France (IDF) or Grand Est (GE)—or in the Nouvelle-Aquitaine (NA)	Men and women, all ages	Men and women, 222 are between 18 and 69 years old, 7 under the age of 18 including 2 who are under 10 years old and one over 80 years old	Individuals receiving routine and other clinical care at Hamad Medical Corporation (HMC), a main provider of healthcare to the urban population of this country and the nationally designated provider for Coronavirus Disease 2019 (COVID-19) healthcare needs
TYPE OF POPULATIONS	Adults	Asymptomatic general population	General population, health care workers	Urban population
SAMPLE SIZE	14,628	13,218	230	112,941
SAMPLING METHOD	Identification of participants in a survey on COVID-19 from an existed consortium based on geographical areas Random sampling	Random sampling	Random sampling	Based on urban areas and medical, Care structures Random sampling
SEROPREVALENCE	Adjusted estimates (positive ELISA-S): 10.0% (95%CI 9.1%;10.9%) in IDF, 9.0% (95%CI 7.7%; 10.2%) in GE and 3.1% (95%CI 2.4%; 3.7%), in NA	A total of 738 citizens tested positive for anti-SRAS-CoV-2 antibodies (398 females, 340 males). The overall prevalence in the sample was 5.6%. Among the HIV-positive citizens, 101 cases were RT-PCR positive (0.76% of the total population). Among citizens aged 14–18 years, 18–65 years and >65 years, seroprevalence was equal to 6.1, 5.6 and 4%, respectively. In the paediatric cohort (<14 years), the seroprevalence was 13%	South East Asia (19.6%, 95% CI 5.5–33.6, all in India) African region (16.3%, 0.0–33.7%). Americas region (6.8%, 5.0–8.5) European Region (4.7%, 3.6–5.9). Western Pacific (1.7%)	13.3% (95% CI: 13.1–13.6%)

(Continued)

Table 1. (Continued)

NUMBER	1.	2.	3.	4.
STUDY PERIOD	May-June 2020	May-2020	December 2019–September 2020	12. May-9. September 2020
RISK FACTORS	Age and the number of child or adolescent lived in the same household, smoking status		Job type, gender	Sex, age, nationality, clinical care type and testing date
SYMPTOMS		Asymptomatic cases		
NUMBER	17.	18.	19.	20
REFERENCE	Della Valle P, Fabbri M, Madotto F, Ferrara P, Cozzolino P, Calabretto E, et al. Occupational Exposure in the Lombardy Region (Italy) to SARS-CoV-2 Infection: Results from the MUSTANG-OCCUPATION-COVID-19 Study. <i>Int J Environ Res Public Health.</i> mars 2021;18(5):2567.	Duan S, Zhou M, Zhang W, Shen J, Qi R, Qin X, et al. Seroprevalence and asymptomatic carrier status of SARS-CoV-2 in Wuhan City and other places of China. <i>PLoS Negl Trop Dis.</i> janv 2021;15(1): e0008975.	Doi A, Iwata K, Kuroda H, Hasuike T, Nasu S, Kanda A, et al. Seroprevalence of novel coronavirus disease (COVID-19) in Kobe, Japan [Internet]. medRxiv; 2020 [cited 2022 Jan 31]. p. 2020.04.26.20079822. Available from: https://www.medrxiv.org/content/10.1101/2020.04.26.20079822v2	Feehan AK, Fort D, Garcia-Diaz J, Price-Haywood E, Velasco C, Sapp E, et al. Point prevalence of SARS-CoV-2 and infection fatality rate in Orleans and Jefferson Parish, Louisiana, May 9–15, 2020 [Internet]. 2020 Jun [cited 2022 Jan 14] p. 2020.06.23.20138321. Available from: https://www.medrxiv.org/content/10.1101/2020.06.23.20138321v1
LOCATION/COUNTRY	Lombardy region, Italy	China (various rights)	Kobe, Japan	New Orleans, Louisiana, USA
SELECTION CRITERIA	Men and women, 18 years old and over	Men and women, all ages	Patients who visited outpatient clinics of the hospital and received blood testing for any reason and not visited the emergency department or the designated fever consultation service	Population representative of the demographics of the Parishes
TYPE OF POPULATIONS	Workers	Healthy general population, asymptomatic cases	General population	Population who lived in Orleans and Jefferson Parishes (representative pool of the demographics of the Parishes)
SAMPLE SIZE	2,255	63,107	1,000	2,640
SAMPLING METHOD	Random sampling	Random sampling	Random sampling	Based on geographical areas, the use of a novel two-step system for representative sample and volunteers with stratification.
SEROPREVALENCE	4.8% tested positive for IgG/IgM antibodies to SARS-CoV-2 antibody test, of which 81.7% were IgG positive only	The total positive SARS-CoV-2 IgG and IgM antibody level was 1.68% (186/11.086) in WH, 0.59% (226/38.171) in Hubei province without Wuhan (HB), 0.38% (53/13.850) in the country excluding Hubei province respectively. The positive IgM rate was 0.46% (51/11.086) in WH 0.13% (51/38.171) in HB and 0.07% (10/13.850) in CN. The incidence of positive IgM levels in healthy individuals increased from 6 March to 3. May 2020 in women and the elderly had a higher probability of being infected than men or younger people	3.3%, 95% CI: 2.3–4.6%	Weight seroprevalence 6.86% (95% CI: 6.8–6.91)
STUDY PERIOD	May-October 2020	March-May 2020	31. March-7. April 2020	9. May-15. May 2020
RISK FACTORS		Children		Ethnicity

(Continued)

Table 1. (Continued)

NUMBER	1.	2.	3.	4.
SYMPTOMS	Cough, sore throat, headache, muscles, anosmia/ageusia, respiratory distress, chest pain, tachycardia, gastrointestinal disorders, conjunctivitis, clinical diagnosis of pneumonia	Asymptomatic cases		
NUMBER	21.	22.	23.	24.
REFERENCE	Feehan AK, Velasco C, Fort D, Burton JH, Price-Haywood E, Katzmarzyk PT, et al. Racial and workplace disparities in seroprevalence of SARS-CoV-2 in Baton Rouge, Louisiana, July 15–31, 2020 [Internet]. 2020 Sep [cited 2022 Jan 20] p. 2020.08.26.20180968. Available from: https://www.medrxiv.org/content/10.1101/2020.08.26.20180968v1	Figar S, Pagotto V, Luna L, Salto J, Manslau MW, Mistchenko AS, et al. Community-level SARS-CoV-2 Seroprevalence Survey in urban slum dwellers of Buenos Aires City, Argentina: a participatory research [Internet]. medRxiv; 2020 [cited 2022 Jan 31]. p. 2020.07.14.20153858. Available from: https://www.medrxiv.org/content/10.1101/2020.07.14.20153858v2	Franceschi VB, Santos AS, Glaeser AB, Paiz JC, Caldana GD, Lessa CLM, et al. Population-based prevalence surveys during the COVID-19 pandemic: a systematic review [Internet]. medRxiv; 2020 [cited 2022 Feb 9]. p. 2020.10.20.20216259. Available from: https://www.medrxiv.org/content/10.1101/2020.10.20.20216259v1	Gégout-Petit A, Jeulin H, Legrand K, Jay N, Bochnakian A, Vallois P, et al. “Seroprevalence of SARS-CoV-2, Symptom Profiles and Sero-Neutralization during the first COVID-19 wave in suburban area, France. medRxiv 2021.02.10.21250862; doi: https://doi.org/10.1101/2021.02.10.21250862
LOCATION/COUNTRY	Baton Rouge, Louisiana	Buenos Aires City, Argentina	Europe: 15 (40.5%) North America: 8 (21.6%) South America: 8 (21.6%) Asia: 5 (13.5%) Africa: 1 (2.7%). In all, 19 countries	Nancy, France
SELECTION CRITERIA	Residents living in eligible ZIP codes and giving consent	Men and women, 14 years old and over	Men and women, all ages	Men and women, 5 years old and over
TYPE OF POPULATIONS	General population	Community (households, families)	General population	General population
SAMPLE SIZE	2,138	873	37 surveys (394,090 + 9,899,828 with the Wuhan’s screening program)	1,11
SAMPLING METHOD	Randomized residents targeted with digital ads for recruitment, then selection based on volunteers and re-stratification by census designation	Selected from a probabilistic sample of households	Random sampling	Randomly sampled from electoral lists and invited with family members
SEROPREVALENCE	3.6% (2.8,4.4)	53.4% (95%IC 52.8% to 54.1%)	19.6% to 69%	2.1%
STUDY PERIOD	15. July-31. July 2020	10. June- 1. July 2020	15. July-5. September 2020	June 2020
RISK FACTORS	Job type	Areas (deprived areas)	Ethnicity/Race, job type, location, deprived area	
SYMPTOMS				Cough, fatigue, shortness of breath, aches anosmia/ageusia, muscle pain, sore throat, headaches, rhinorrhea, chest pain, diarrhea, abdominal pain, loss of balance, nausea, appetite loss, skin rashes, irritated eye
NUMBER	25	26	27	28
REFERENCE	George CE, Inbaraj LR, Chandrasingh S, de Witte LP. High seroprevalence of COVID-19 infection in a large slum in South India; what does it tell us about managing a pandemic and beyond? <i>Epidemiol Infect.</i> 4 févr 2021;149:e39.	Ghose A, Bhattacharya S, Karthikeyan AS, Kudale A, Monteiro JM, Joshi A, et al. Community prevalence of antibodies to SARS-CoV-2 and correlates of protective immunity in an Indian metropolitan city [Internet]. medRxiv; 2020 [cited 2022 Jan 31]. p. 2020.11.17.20228155. Available from: https://www.medrxiv.org/content/10.1101/2020.11.17.20228155v2	Grant R, Dub T, Andrianou X, Nohynek H, Wilder-Smith A, Pezzotti P, et al. SARS-CoV-2 population-based seroprevalence studies in Europe: a scoping review. <i>BMJ Open.</i> 1 avr 2021;11(4):e045425.	Hallal PC, Hartwig FP, Horta BL, Silveira MF, Struchiner CJ, Vidaletti LP, et al. SARS-CoV-2 antibody prevalence in Brazil: results from two successive nationwide serological household surveys. <i>Lancet Glob Health.</i> nov 2020;8(11):e1390-8.
LOCATION/COUNTRY	South India	India (a metropolitan city)	Europe	Brazil (133 cities)

(Continued)

Table 1. (Continued)

NUMBER	1.	2.	3.	4.
SELECTION CRITERIA	Men and women, 18 years and over, (74.3%) were women	Live in an inactive containment zone, healthy subjects who not presented fever, not had an illness episode including COVID-19 in the past	Men and women, all ages	Men and women, all ages
TYPE OF POPULATIONS	Population from a large slum with about one third of the population reported comorbidities.	Adults living in a metropolitan city	General population	General population
SAMPLE SIZE	499	1,659	194	25,025 (14–21 May), 31,165 (4–7 June)
SAMPLING METHOD	Random sampling	Sub-wards randomly selected and Stratified by incidence (based on areas and incidence)	Random sampling	Random sampling (in the list of members of the households provided)
SEROPREVALENCE	The overall seroprevalence of IgG antibody to COVID-19 was 57.9% The ratio of undetected cases to infections was 1: 195 and the case fatality rate was calculated as 2.94 per 10.000 infections	(51.3%; 95%CI 39.9 to 62.4)	Between 0.42% and 23.3% positives cases Residual clinical: Greece: 0.42% Germany: 13.6% Blood Donors: Northwest Germany: 0.91% Lombardy, Italy: 23.3%	9,259 positive cases of 25.025 i.e. 37%
STUDY PERIOD	October- 2020	20. July-5. August 2020	January-September 2020	May-June 2020
RISK FACTORS		Living conditions, age	The most densely populated centres were the most affected by COVID-19	The most densely populated centres were the most affected by COVID-19 Age, Young people (between 18–30 years old)
SYMPTOMS				
NUMBER	29.	30.	31.	32.
REFERENCE	Havers FP, Reed C, Lim T, Montgomery JM, Klena JD, Hall AJ, et al. Seroprevalence of Antibodies to SARS-CoV-2 in 10 Sites in the United States , March 23–May 12, 2020. JAMA Intern Med. 21 juill 2020;	He Z, Ren L, Yang J, Guo L, Feng L, Ma C, et al. Seroprevalence and humoral immune durability of anti-SARS-CoV-2 antibodies in Wuhan, China: a longitudinal, population-level, cross-sectional study . Lancet. 20 mars 2021;397(10279):1075–84.	Hozé N, Paireau J, Lapidus N, Tran Kiem C, Salje H, Severi G, et al. Monitoring the proportion of the population infected by SARS-CoV-2 using age-stratified hospitalisation and serological data: a modelling study . Lancet Public Health. 8 avr 2021;	Husby A, Corn G, Krause TG. SARS-CoV-2 infection in households with and without young children: Nationwide cohort study [Internet]. 2021 Mar [cited 2022 Jan 20] p. 2021.02.28.21250921. Available from: https://www.medrxiv.org/content/10.1101/2021.02.28.21250921v1
LOCATION/COUNTRY	United States	Wuhan, China	France	Denmark
SELECTION CRITERIA	Men and women, 18 years old or younger and over 65 years old	Men and women, all ages, asymptomatic cases	Men and women, 20 years old and over	Men and women, 18–60 years old
TYPE OF POPULATIONS	General population	General population	Proportion of adults infected with SARS-CoV-2 and the proportion of infections detected in the two most affected regions in France in May 2020, applied our approach to the 13 French metropolitan regions over the period	We constructed a cohort of SARS-CoV-2-test-positive individuals who were followed up for hospitalization until 30 days after positive test.
SAMPLE SIZE	16,025	9,542 from 3,556 families	9,782	449,915 living in households with young children, while among 2,629,821 without young children in their household
SAMPLING METHOD	A practical sample of residual seraglio	Random sampling Those who had been living in Wuhan for at least 14 days since 1 December 2019	Random sampling	Random sampling

(Continued)

Table 1. (Continued)

NUMBER	1.	2.	3.	4.
SEROPREVALENCE	1,0% to6,9%	Between 5-and 6%	5–7% (95% CI 5-1-6-4) of adults in metropolitan France had been infected with SARS-CoV-2 by 11 May 2020. This proportion remained stable until August 2020 and increased to 14–9% (13-2-16-9) by 15 January 2021. With 26–5% (23-4-29-8) of adult residents having been infected in Île-de-France (Paris region) compared to 5–1% (4-5-5-8) in Brittany in January 2021, regional variations remained significant (coefficient of variation [CV] 0–50) although less so than in May 2020 (CV 0–74). The proportion infected was twice as high (20–4%, 15-6-26-3) among 20–49 year olds than among those aged 50 years or more (9–7%, 6-9-14-1). 40–2% (34-3-46-3) of adult infections were detected in June to August 2020, compared to 49–3% (42-9-55-9) in November, 2020, to January, 2021	-Among 449.915 samples living in households with young children, 5.761 (1.28%)were tested positive for SARS-CoV-2 -Among 2.629.821 adults without young children in their household, 33.788 (1.28%) were tested positive for SARS-CoV-2 (adjusted hazard ratio, 1.05; 95% confidence interval, 1.02 to 1.09)
STUDY PERIOD	March-May 2020	April-December 2020	March 2020-February 2021	27. February-15. November 2020
RISK FACTORS				Age, gender, with or without children at household (the number), ethnicity, comorbidities (Asthma, Chronic pulmonary disease, Cardiovascular disease, Diabetes mellitus, Inflammatory bowel disease Malignancy, Renal failure)
SYMPTOMS	Mild symptoms	Respiratory symptoms, asymptomatic cases		
NUMBER	33.	34.	35.	36.
REFERENCE	Hussein NR, Balatay AA, Naqid IA, Jamal SA, Rasheed NA, Ahmed AN, et al. COVID-19 antibody seroprevalence in Duhok, Kurdistan Region, Iraq: A population-based study [Internet]. medRxiv; 2021 [cited 2022 Feb 9]. p. 2021.03.23.21254169. Available from: https://www.medrxiv.org/content/10.1101/2021.03.23.21254169v1	Inbaraj LR, George CE, Chandrasingh S. Seroprevalence of COVID-19 infection in a rural district of South India: A population-based seroepidemiological study. PloS One. 2021;16(3):e0249247.	Investigators A to beat coronavirus/Action pour battre le coronavirus (Ab-CS, Jha P. COVID Seroprevalence, Symptoms and Mortality During the First Wave of SARS-CoV-2 in Canada [Internet]. 2021 Mar [cited 2022 Jan 20] p. 2021.03.04.21252540. Available from: https://www.medrxiv.org/content/10.1101/2021.03.04.21252540v1	Investigators RS, Riley S, Ainslie KEC, Eales O, Jeffrey B, Walters CE, et al. Community prevalence of SARS-CoV-2 virus in England during May 2020: REACT study [Internet]. medRxiv; 2020 [cited 2022 Feb 2]. p. 2020.07.10.20150524. Available from: https://www.medrxiv.org/content/10.1101/2020.07.10.20150524v1
LOCATION/COUNTRY	Duhok City, Iraq	South India	Canada	United Kingdom, England
SELECTION CRITERIA	Men and women, all ages	Men and women, 18 years old and over	Men and women, 18 years old and over	Men and women, 5 years old and over
TYPE OF POPULATIONS	We included samples from both urban and rural populations (General population) A person was eligible to be included in the study if the person was at least 16 years old, was a resident of one of the considered districts, had been living at a specific address for at least 6 months	Population of two grampanchayats (administrative group of 5 to 8 villages). Four sub-districts	General population, national demographic Distribution and Forum panel members who lived in 17 pre-defined public health regions	General population: Participants were randomly selected from the National Health Service (NHS) list of patients registered with a general practitioner

(Continued)

Table 1. (Continued)

NUMBER	1.	2.	3.	4.
SAMPLE SIZE	743	509	We surveyed a representative sample of 19,994 Canadians about COVID symptoms and analyzed IgG antibodies against SARS-CoV-2 from self-collected dried blood spots in 8,967 samples	120,610
SAMPLING METHOD	Random sampling	Random sampling	Stratified samples	Random sampling
SEROPREVALENCE	Among the participants, 465/743 (62.58%) tested positive for antibodies. Among the participants with antibodies, 262/465 (56.34%) denied having any history of COVID-19 related symptoms	The age and gender adjusted seroprevalence was 8.5%. The unadjusted seroprevalence in participants with hypertension and diabetes was 16.3% and 10.7% respectively When we adjusted for test performance, the seroprevalence was 6.1% The study estimated that 7 undetected infected persons for each case confirmed by RT-PCR The infection mortality rate (IFR) was calculated to be 12.38 per 10,000 infections as of 22 October 2020	The best estimate of adult seroprevalence nationally is 1.7%, but as high as 3.5% depending on assay cut-offs. The highest prevalence was in Ontario (2.4–3.9%) and in younger adults aged 18–39 years (2.5–4.4%).	We found 159 positives from 120,610 swabs giving an average prevalence of 0.13% (95% CI: 0.11%, 0.15%) Adults aged 18 to 24 yrs had the highest swab-positivity rates, while those >64 yrs had the lowest
STUDY PERIOD	July 2020–February 2021	May–September 2020	May–September 2020	1. May–1. June 2020
RISK FACTORS	Gender, marital status, chronic disease		Gender, age, location, education, household size, ethnicity, smoking	Age, ethnicity, location, job
SYMPTOMS	Fever, myalgia, loss of smell and taste, shortness of breath, cough, diarrhea, headache A total of 203/465 (43.66%) participants had a history of different symptoms		Fever, difficult breathing, dry cough, loss of smell, “Covid toe”	Asymptomatic cases, nausea and/or vomiting, diarrhoea, blocked nose, loss of smell, loss of taste, headache, chills and severe fatigue
NUMBER	37.	38.	39.	40.
REFERENCE	Javed W, Baqar JB, Abidi SHB, Farooq W. Seroprevalence Findings from Metropolises in Pakistan: Implications for Assessing COVID-19 Prevalence and Case-fatality within a Dense, Urban Working Population [Internet]. medRxiv; 2020 [cited 2022 Feb 9]. p. 2020.08.13.20173914. Available from: https://www.medrxiv.org/content/10.1101/2020.08.13.20173914v1	Jõgi P, Soeorg H, Ingerainen D, Soots M, Lättেকivi F, Naaber P, et al. Seroprevalence of SARS-CoV-2 IgG antibodies in two regions of Estonia (KoroSero-EST-1) [Internet]. 2020 Oct [cited 2022 Jan 20]. p. 2020.10.21.20216820. Available from: https://www.medrxiv.org/content/10.1101/2020.10.21.20216820v1	Khalagi K, Gharibzadeh S, Khalili D, Mansournia MA, Samiee SM, Aghamohamadi S, et al. Prevalence of COVID-19 in Iran: Results of the first survey of the Iranian COVID-19 Serological Surveillance program [Internet]. medRxiv; 2021 [cited 2022 Feb 9]. p. 2021.03.12.21253442. Available from: https://www.medrxiv.org/content/10.1101/2021.03.12.21253442v2	Kshatri JS, Bhattacharya D, Kanungo S, Giri S, Palo SK, Parai D, et al. Findings from serological surveys (in August 2020) to assess the exposure of adult population to SARS Cov-2 infection in three cities of Odisha, India [Internet]. medRxiv; 2020 [cited 2022 Feb 9]. p. 2020.10.11.20210807. Available from: https://www.medrxiv.org/content/10.1101/2020.10.11.20210807v1
LOCATION/COUNTRY	Metropolises of Pakistan (Karachi, Lahore, Multan, Peshawar and Quetta)	In two regions (Harju county and in Saaremaa), Estonia	Iran (all provinces)	Odisha, Eastern India
SELECTION CRITERIA	Men and women, 18–65 years old	Men and women, 0–100 years old	Men and women, 6 years old and over	Men and women, 18 years old and over
TYPE OF POPULATIONS	General population The sample size included an adult, working population aged 18–65 years, recruited from dense, urban workplaces including factories, corporates, restaurants, media houses, schools, banks, healthcare providers in hospitals, and families of positive cases	Patients of two general practitioner in Estonia.	General population	General population, residing in the city since at least the past 3 months.
SAMPLE SIZE	24,210	1,960	11,256	4,146
SAMPLING METHOD	Random sampling	Stratified random sampling	Stratified random sampling	Multistage random sampling

(Continued)

Table 1. (Continued)

NUMBER	1.	2.	3.	4.
SEROPREVALENCE	The study results reveal that from 24,210 individuals screened, 17.5% tested positive, with 7% IgM positive, 6.0% IgG positive and 4.5% combined IgM and IgG positive.	Seroprevalence was 1.5% (95% confidence interval (CI) 0.9–2.5) and 6.3% (95% CI 5.0–7.9), infection fatality rate 0.1% (95% CI 0.0–0.2) and 1.3% (95% CI 0.4–2.1) in Tallinn and Saaremaa, respectively.	Prevalence of COVID-19 until August 20, 2020 was estimated as 14.2% (95% uncertainty interval: 13.3%, 15.2%), which was equal to 11,958,346 (95% confidence interval: 11,211,011–12,746,776) individuals. The prevalence of infection was 14.6%, 13.8%, 16.6%, 11.7%, and 19.4% among men, women, urban population, rural population, and individuals ≥ 60 years of age, respectively	Berhampur: 31.14% (95% CI:28.69–33.66%) Rourkela: 24.59% (95% CI:22.39–26.88%) Bhubaneswar: 5.24% (95% CI:4.10–6.58%)
STUDY PERIOD	July-2020	8. May-31. July 2020	August-October 2020	August-2020
RISK FACTORS	Job, age, location, family contact cases	Age, gender, household size, contact with confirmed case Of seropositive subjects 19.2% (14/73) had acute respiratory illness. IgG concentrations were higher if fever, difficulty breathing, shortness of breath, chest pain or diarrhea was present, or hospitalization required	Gender, age, location (urban/rural population)	Gender (females reported a higher seroprevalence with 22.8% as compared to males with 18.8%)
SYMPTOMS	Mild symptoms	Fever, diarrhea and the absence of cough and runny nose were associated with seropositivity in individuals aged 50 or more years	Mild symptoms, asymptomatic cases	Majority Asymptomatic with 93.87% Symptoms: -Fever (68.89%) -Cough (46.06%) -Myalgia (32.67%)
NUMBER	41.	42.	43	44.
REFERENCE	Ladage D, Höglinger Y, Ladage D, Adler C, Yalcin I, Braun RJ. SARS-CoV-2 antibody prevalence and symptoms in a local Austrian population [Internet]. 2020 Nov [cited 2022 Jan 20] p. 2020.11.03.20219121. Available from: https://www.medrxiv.org/content/10.1101/2020.11.03.20219121v1	Lastrucci V, Lorini C, Del Riccio M, Gori E, Chiesi F, Sartor G, et al. SARS-CoV-2 Seroprevalence Survey in People Involved in Different Essential Activities during the General Lock-Down Phase in the Province of Prato (Tuscany, Italy) . Vaccines. 19 déc 2020;8(4).	Lavezzo E, Franchin E, Ciavarella C, Cuomo-Dannenburg G, Barzon L, Del Vecchio C, et al. Suppression of a SARS-CoV-2 outbreak in the Italian municipality of Vo' . Nature. 2020 Aug;584(7821):425–9.	Levorson RE, Christian E, Hunter B, Sayal J, Sun J, Bruce SA, et al. SARS-CoV-2 Seroepidemiology in Children and Adolescents [Internet]. medRxiv; 2021 [cited 2022 Jan 31]. p. 2021.01.28.21250466. Available from: https://www.medrxiv.org/content/10.1101/2021.01.28.21250466v1
LOCATION/COUNTRY	Austria	Province of Prato, (Tuscany, Italy)	Italia	Northern Virginia, United States
SELECTION CRITERIA	Inhabitants of an Austrian township with a reported higher incidence for COVID-19 infection	Men and women, all ages	Men and women, all ages	Children and adolescents ≤ 19 years
TYPE OF POPULATIONS	General population (inhabitants of a township)	People who had carried out essential activities during the period of confinement	Population residents (General population)	Children and adolescents and Residence in Virginia
SAMPLE SIZE	835	4,656	5,155	1,038
SAMPLING METHOD	Based on location (towns) and incidence, then voluntary (recruiting with a Public call supported by local authorities)	Random sampling	Random sampling	Recruited from three settings in Northern Virginia (non-emergency health care settings, self-referral, the Inova Children's Hospital Pediatric Emergency Department)

(Continued)

Table 1. (Continued)

NUMBER	1.	2.	3.	4.
SEROPREVALENCE	9%	138 positive cases i.e. 2.96%	A total of 73 out of the 2,812 participants who were tested at the first survey were positive, which gives a prevalence of 2.6% (95% CI: 2.1–3.3%). The second survey identified 29 total positive cases (prevalence of 1.2%; 95% CI: 0.8–1.8%), 8 of which were new cases (prevalence of 0.3%; 95% CI: 0.15–0.7%)	8.5%
STUDY PERIOD	June-2020	May-2020	February-March 2020	31. July-13. October 2020
RISK FACTORS			Age, sex	Ethnicity, public or absent insurance, a history of COVID-19 symptoms, exposure to person with COVID-19, a household member positive for SARS-CoV-2 and multi-family or apartment dwelling without a private entrance.
SYMPTOMS			Asymptomatic cases, fever, cough, headache, sorethroat, diarrhea, malaise, conjunctivitis	A history of COVID-19 symptoms
NUMBER	45.	46.	47.	48.
REFERENCE	Levesque J, Maybury DW. A note on COVID-19 seroprevalence studies: a meta-analysis using hierarchical modelling [Internet]. 2020 May [cited 2022 Jan 14] p. 2020.05.03.20089201. Available from: https://www.medrxiv.org/content/10.1101/2020.05.03.20089201v1	Lim T, Delorey M, Bestul N, Johannsen M, Reed C, Hall AJ, et al. Changes in SARS CoV-2 Seroprevalence Over Time in Ten Sites in the United States, March—August, 2020 . Clin Infect Dis Off Publ Infect Dis Soc Am. 26 févr 2021;	Ling R, Yu Y, He J, Zhang J, Xu S, Sun R, et al. Seroprevalence and epidemiological characteristics of immunoglobulin M and G antibodies against SARS-CoV-2 in asymptomatic people in Wuhan, China: a cross-sectional study [Internet]. 2020 Aug [cited 2022 Jan 20] p. 2020.06.16.20132423. Available from: https://www.medrxiv.org/content/10.1101/2020.06.16.20132423v3	Malani A, Shah D, Kang G, Lobo GN, Shastri J, Mohanan M, et al. Seroprevalence of SARS-CoV-2 in slums and non-slums of Mumbai, India, during June 29-July 19, 2020 [Internet]. 2020 Sep [cited 2022 Jan 14] p. 2020.08.27.20182741. Available from: https://www.medrxiv.org/content/10.1101/2020.08.27.20182741v1
LOCATION/COUNTRY	European (Gangelt, Germani/Geneva, Switzerland) American locations (Chelsea, Massachusetts/ San Miguel County, Colorado/ Los Angeles County, California)	United States (10 sites)	Wuhan, China	Mumbai, India
SELECTION CRITERIA	Men and women, all ages	Men and women, all ages	All ages with no fever, headache or other symptoms of COVID-19 and residents in Wuhan	Men and women, 12 years old and over
TYPE OF POPULATIONS	General population	General population	Asymptomatic general population	People from slum and non-slum communities
SAMPLE SIZE	9,663	1,800	18,712	6,609 (4,202 from slums and 2,702 from non-slums)
SAMPLING METHOD	Random sampling	A convenient sample of residual seraglio, Random sampling	Open screening proposed to all residents of Wuhan, screening carried out in hospital	Random sampling
SEROPREVALENCE	Geneva: In the week of April 6 to 10, researchers found that 3.5% of the 343 participants tested positive, which we interpret as 12 individuals. In the week of April 14 to 17, they found that 5.5% of the 417 participants tested positive, which we interpret as 23 individuals Chelsea: 63 tested positive of 200 samples (31.5%) San Miguel County: 96 total positive tests, out of 4,757 (2.01%) Santa Clara County: 2.81% Los Angeles County: Out of 863 participants, 4.1% tested positive, which we interpret as 35 individuals. The researchers reported the 95% confidence bounds on the prevalence of 2.8%, and 5.6%	Seroprevalence remained below 10% in all sites except New York and Florida, where it reached 23.2% and 13.3% respectively. New York and Florida, where it reached 23.2% and 13.3% respectively.	Age and gender adjust: 3.27(3.02–3.52) Assay adjust: 2.72 (2.49–2.95)	The positive test rate was 54.1% (95% CI: 52.7 to 55.6) and 16.1% (95% CI: 14.9 to 17.4) in slums and non-slums, respectively, a difference of 38 percentage points (P < 0.001). Accounting for imperfect accuracy of tests (e.g., sensitivity, 0.90; specificity 1.00), seroprevalence was as high as 58.4% (95% CI: 56.8 to 59.9) and 17.3% (95% CI: 16 to 18.7) in slums and non-slums, respectively

(Continued)

Table 1. (Continued)

NUMBER	1.	2.	3.	4.
STUDY PERIOD	30. March-21. April 2020	March-August 2020	25. March- 28. April 2020	29. June-19. July 2020
RISK FACTORS			Sex, geographic areas, different types of workplaces	Location, age, gender
SYMPTOMS			Asymptomatic cases	
NUMBER	49.	50.	51.	52.
REFERENCE	McLaughlin CC, Doll MK, Morrison KT, McLaughlin WL, O'Connor T, Sholukh AM, et al. High Community SARS-CoV-2 Antibody Seroprevalence in a Ski Resort Community, Blaine County, Idaho, US. Preliminary Results. MedRxiv Prepr Serv Health Sci. 21 juill 2020;	Melotti R, Scaggiante F, Falciani M, Weichenberger CX, Foco L, Lombardo S, et al. Prevalence and determinants of serum antibodies to SARS-CoV-2 in the general population of the Gardena Valley [Internet]. 2021 Mar [cited 2022 Jan 20] p. 2021.03.19.21253883. Available from: https://www.medrxiv.org/content/10.1101/2021.03.19.21253883v1	Menachemi N, Yiannoutsos CT, Dixon BE, Duszynski TJ, Fadel WF, Wools-Kaloustian KK, et al. Population Point Prevalence of SARS-CoV-2 Infection Based on a Statewide Random Sample—Indiana, April 25–29, 2020. MMWR Morb Mortal Wkly Rep. 24 juill 2020;69(29):960-4.	Merkely B, Szabó AJ, Kosztin A, Berényi E, Sebestyén A, Lengyel C, et al. Novel coronavirus epidemic in the Hungarian population, a cross-sectional nationwide survey to support the exit policy in Hungary. GeroScience 2020;42:1063–74.
LOCATION/COUNTRY	Blaine County, Idaho, United States	Gardena Valley	Indiana	Hungary
SELECTION CRITERIA	No criteria, all the population of the county concerned, 18 years and older	Selected with known extraction probability from the municipality registries, excluding nursing homes	Elderly population and in racial and ethnic minority communities	Men and women, 14 years old and over
TYPE OF POPULATIONS	The residents of this county	General population	Elderly samples and in racial and ethnic minority communities	Private households
SAMPLE SIZE	917	2,244	3,658	10,474
SAMPLING METHOD	Selection from volunteers who have registered via a secure web link, using the weighting of the pre-stratification to the distribution of the population by age and gender in each postal code	One-stage random sampling design stratified by municipality, gender and age group	Random sampling	Two-stage stratified probability sample of individuals was selected from the population registry,
SEROPREVALENCE	The range of seroprevalence after correction for potential selection bias was 21.9% to 24.2% That is 208 out of 917 is positive	26.9% (95% confidence interval: 25.2%, 28.6%) in June 2020	1,74	3 had positive PCR and 69 had positive serological test
STUDY PERIOD	April-June 2020	26. May-8. June 2020	April-2020	March-2020
RISK FACTORS		Place of residence, economic activity		Sex, activity professional, Place of work during the epidemic, smocking, comorbidities (hypertension, heart disease, diabetes milletus, chronic pulmonary disease, chronic renal disease, chronic liver disease, curretn malignancy, immunodeficiency)
SYMPTOMS		Loss of taste or smell, fever, difficulty in breathing, pain in the limbs, and weakness		Fever, fatigue, body aches, cough, headache, sore throat, shortness of breath, abdominal pain, nausea/vomiting, diarrhea, loss smell or taste
NUMBER	53.	54.	55	56.

(Continued)

Table 1. (Continued)

NUMBER	1.	2.	3.	4.
REFERENCE	Murhekar MV, Bhatnagar T, Selvaraju S, Saravanakumar V, Thangaraj JWV, Shah N, et al. SARS-CoV-2 antibody seroprevalence in India, August-September, 2020: findings from the second nationwide household serosurvey. <i>Lancet Glob Health.</i> mars 2021;9(3):e257-66.	Murhekar MV, Bhatnagar T, Selvaraju S, Rade K, Saravanakumar V, Vivian Thangaraj JW, et al. Prevalence of SARS-CoV-2 infection in India: Findings from the national serosurvey, May-June 2020. <i>Indian J Med Res.</i> août 2020;152(1 & 2):48-60.	Naranbhai V, Chang CC, Beltran WFG, Miller TE, Astudillo MG, Villalba JA, et al. High Seroprevalence of Anti-SARS-CoV-2 Antibodies in Chelsea, Massachusetts. <i>J Infect Dis.</i> 13 nov 2020;222(12):1955-9.	Naushin S, Sardana V, Ujjainiya R, Bhatheja N, Kutum R, Bhaskar AK, et al. Insights from a Pan India Sero-Epidemiological survey (Phenome-India Cohort) for SARS-CoV-2 [Internet]. 2021 Feb [cited 2022 Jan 14] p. 2021.01.12.21249713. Available from: https://www.medrxiv.org/content/10.1101/2021.01.12.21249713v2
LOCATION/COUNTRY	India	India	Chelsea, Massachusetts	India (17 States and two Union Territories)
SELECTION CRITERIA	Men and women, 10 years old and older	Men and women, all ages	Men and women, all ages	Men and women, all ages
TYPE OF POPULATIONS	General population, in the same 700 villages or neighbourhoods in 70 districts in India that were included in the first serosurvey	General population	Asymptomatic general population	Adult subjects working in CSIR laboratories and their family members (General population)
SAMPLE SIZE	29,082	30,283 households were visited, 28,000 samples were registered	200	10,427
SAMPLING METHOD	Random sampling	Random sampling	Anonymised sampling for convenience	Random sampling
SEROPREVALENCE	The adjusted weighted seroprevalence of SARS-CoV-2 IgG antibodies in individuals aged 10 years or older was 6–6% (95% CI 5-8-7-4). Among 15,084 randomly selected adults (one per household), the adjusted weighted seroprevalence was 7–1% (6-2-8-2)	The population-weighted seroprevalence after adjustment for test performance was 0.73% [95% confidence interval (CI): 0.34–1.13]. [95% confidence interval (CI): 0.34–1.13]	31.5%, 24.8% (25/101) were positive and 60% were IgM+IgG-.	10.14%
STUDY PERIOD	August-September 2020	May-June 2020	March-April 2020	August-September 2020
RISK FACTORS			The most densely populated centres were the most affected by COVID-19 Low income, presence of an seropositive case in the household	Age, gender
SYMPTOMS	Mild symptoms	486 cases (1.7%) respiratory symptoms	50.5% reported no symptoms (asymptomatic cases) in the previous four weeks Symptoms in the Last 4 Weeks: The most common symptoms reported were: -Cough (26.5%), -Rhinitis (24.0%), -Sore throat (23.5%), -Myalgia (23.0%). 13.0% reported a reduced sense of smell or taste. 16.9% thought they had or have had COVID-19 illness.	Asymptomatic Symptoms: -Fever (50%) -Loss of smell and taste (25%)
NUMBER	57.	58.	59.	60.
REFERENCE	Nawa N, Kuramochi J, Sonoda S, Yamaoka Y, Nukui Y, Miyazaki Y, et al. Seroprevalence of SARS-CoV-2 IgG Antibodies in Utsunomiya City, Greater Tokyo, after first pandemic in 2020 (U-CORONA): a household- and population-based study [Internet]. 2020 Jul [cited 2022 Jan 20] p. 2020.07.20.20155945. Available from: https://www.medrxiv.org/content/10.1101/2020.07.20.20155945v1	Noh J, Danuser G. Estimation of the fraction of COVID-19 infected people in US states and countries worldwide. <i>Plos One.</i> 8 févr 2021;16(2):e0246772.	Pagani G, Conti F, Giacomelli A, Bernacchia D, Rondonan R, Prina A, et al. Seroprevalence of SARS-CoV-2 significantly varies with age: Preliminary results from a mass population screening. <i>J Infect.</i> déc 2020;81(6):e10-2.	Pan Y, Li X, Yang G, Fan J, Tang Y, Hong X, et al. Seroprevalence of SARS-CoV-2 immunoglobulin antibodies in Wuhan, China: part of the city-wide massive testing campaign. <i>Clin Microbiol Infect.</i> févr 2021;27(2):253-7.

(Continued)

Table 1. (Continued)

NUMBER	1.	2.	3.	4.
LOCATION/ COUNTRY	Utsunomiya City, Tokio	United States	Castiglione d'Adda, south-east Milan, Italy	Wuhan, China
SELECTION CRITERIA	Men and women, all ages	Men and women, all ages	Men and women, all ages	Men and women, all age
TYPE OF POPULATIONS	General population (resident in Utsunomiya City)	General population	General population	General population
SAMPLE SIZE	742		509	61,437
SAMPLING METHOD	Random sampling	Random sampling	Random sampling	Random cluster sampling
SEROPREVALENCE	0.43% to 1.23%	Between 2,5 and-22,4% positives cases	22.60%	A total of 1.470 individuals tested positive for at least one antiviral antibody. Of the positive individuals, 324 (0.53%, 95% CI 0.47–0.59) and 1.200 (1.95%, 95% CI 1.85–2.07) were positive for IgM and IgG immunoglobulin, respectively, and 54 (0.08%, 95% CI 0.07–0.12) were positive for both antibodies. The positive rate of female antibody carriers was higher than that of male counterparts (male to female ratio). Male counterparts (male-to- female ratio 0.75), particularly among older citizens (ratio of 0.18 in the 90+ age subgroup) This indicates a gender gap in seroprevalence. In addition, viral nucleic acid detection using real- time pcr showed 8 (0.013%, 95% CI 0.006–0.026) asymptomatic virus carriers
STUDY PERIOD	14. June-5. July 2020	March-April 2020	May-June 2020	May-2020
RISK FACTORS	Age, gender, number cohabitant, residential district			
SYMPTOMS	Symptoms: -Afebrile		Fever, cough, anosmia, dysgeusia, dispnea	
NUMBER	61.	62.	63.	64.
REFERENCE	Parker DM, Bruckner T, Vieira VM, Medina C, Minin VN, Felgner PL, et al. Epidemiology of the early COVID-19 epidemic in Orange County, California: comparison of predictors of test positivity, mortality, and seropositivity [Internet]. 2021 Jan [cited 2022 Jan 14] p. 2021.01.13.21249507. Available from: https:// www.medrxiv.org/content/10.1101/2021.01.13. 21249507v2	Pérez-Olmeda M, Saugar JM, Fernández-García A, Pérez- Gómez B, Pollán M, Avellón A, et al. Evolution of antibodies against SARS-CoV-2 over seven months: experience of the Nationwide Seroprevalence ENE-COVID Study in Spain [Internet]. 2021 Mar [cited 2022 Jan 20] p. 2021.03.11.21253142. Available from: https://www. medrxiv.org/content/10.1101/ 2021.03.11.21253142v1	Petersen MS, Strøm M, Christiansen DH, Fjallsbak JP, Eliassen EH, Johansen M, et al. Seroprevalence of SARS-CoV- 2-Specific Antibodies, Faroe Islands. Emerg Infect Dis. nov 2020;26(11):2761-3.	Poljak M, Valenčak AO, Štrumbelj E, Vodičar PM, Vehovar V, Rus KR, et al. Seroprevalence of SARS-CoV-2 in Slovenia: results of two rounds of a nationwide population study on a probability-based sample, challenges and lessons learned. Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis. 7 avr 2021;
LOCATION/ COUNTRY	Orange County, California	Spain	Faroe Islands	Slovenia
SELECTION CRITERIA	Men and women, all ages	Men and women, all ages	Men and women, 18 years old and over	Men and women, all ages
TYPE OF POPULATIONS	General population	The community-dwelling population in general population	General population	General population

(Continued)

Table 1. (Continued)

NUMBER	1.	2.	3.	4.
SAMPLE SIZE	318,492	10,153	1,075	3,000
SAMPLING METHOD	Random sampling	A two-stage sampling stratified	From the Faroe Islands population register, they sampled 1,500 people and invited them by letter to a clinic visit. Those unable to attend a test site received a home visit	Random sampling
SEROPREVALENCE	36,816 tested positive for COVID-19	2,595 participants 44 (35.1% of participants) were positive for anti-nucleocapsid IgG in at least one round. In fourth round, anti-nucleocapsid and anti-RBD IgG were detected in 5.5% and 5.4% participants of the randomly selected sub-cohort, and in 26.6% and 25.9% participants with at least one previous positive result, respectively	0,7% 7 positive cases of 1.075 samples	SARS-CoV-2 seroprevalence in Slovenia increased fourfold from late April to October/November 2020, mainly due to a devastating second wave. Between 2.78 and-4.29%
STUDY PERIOD	January 2020–16. August 2020	15. March-06. December 2020	April-May 2020	April-November 2020
RISK FACTORS	Age, gender, race/ethnicity, % college degree, % with insurance			
SYMPTOMS				
NUMBER	65.	66.	67	68
REFERENCE	Pollán M, Pérez-Gómez B, Pastor-Barriuso R, Oteo J, Hernán MA, Pérez-Olmeda M, et al. Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study. Lancet Lond Engl. 22 août 2020;396(10250):535-44.	Polvere I, Parrella A, Casamassa G, D'Andrea S, Tizzano A, Cardinale G, et al. Seroprevalence of Anti-SARS-CoV-2 IgG and IgM among Adults over 65 Years Old in the South of Italy. Diagnostics. mars 2021;11(3):483.	Poustchi H, Darvishian M, Mohammadi Z, Shayanrad A, Delavari A, Bahadorimonfared A, et al. SARS-CoV-2 antibody seroprevalence in the general population and high-risk occupational groups across 18 cities in Iran: a population-based cross-sectional study. Lancet Infect Dis. avr 2021;21(4):473-81.	Pritsch M, Radon K, Bakuli A, Le Gleut R, Olbrich L, Guggenbuehl Noller JM, et al. Prevalence and Risk Factors of Infection in the Representative COVID-19 Cohort Munich. Int J Environ Res Public Health. 30 mars 2021;18(7).
LOCATION/COUNTRY	Spain	Southern Italy	Iran	Munich, German
SELECTION CRITERIA	Men and women, all ages	Men and women, 65 years old and over	Men and women, 18 years old and over	Men and women, all ages
TYPE OF POPULATIONS	All residents were invited to participate, with asymptomatic cases	General population	General population	General population
SAMPLE SIZE	61,075	1,383	8,902	5,313
SAMPLING METHOD	Random sampling in two stages stratified by province size and the municipality	Random sampling	Random sampling	Representative sample, Random sampling
SEROPREVALENCE	The seroprevalence was 5–0% (95% CI 4-7-5-4) by the point-of-care test and 4–6% (4-3-5-0) byimmunoassay, with a specificity-sensitivity range of 3–7% (3-3-4-0; both tests positive) to 6–2% (5-8-6-6; either test positive), with no gender differences and lower seroprevalence in children under 10 years of age (<3–1% by point-of-care test)	The overall seroprevalence of anti-SRAS-CoV-2 antibodies was 4.70%. statistically significant differences between the sexes. Of these, 69.69% were IgM positive, 23.08% IgG and 9.23% were positive for both.	17.10%	SARS-CoV-2 specific antibody seropositivity was 1.82% (95% confidence interval (CI) 1.28–2.37%). compared to 0.46% of officially registered pcr positive cases in Munich
STUDY PERIOD	April-May 2020	September-2020	April-June 2020	April-June 2020
RISK FACTORS			Disadvantaged areas	

(Continued)

Table 1. (Continued)

NUMBER	1.	2.	3.	4.
SYMPTOMS	Anosmia or three or more symptoms compatible with COVID-19 was 49.1%, asymptomatic cases		-Anosmia 75.0%, -Fever 60.8%	
NUMBER	69.	70.	71.	72.
REFERENCE	Qin X, Shen J, Dai E, Li H, Tang G, Zhang L, et al. The seroprevalence and kinetics of IgM and IgG in the progression of COVID-19. BMC Immunol. 17 févr 2021;22(1):14.	Qutob N, Awartani F, Salah Z, Asia M, Abu Khader I, Herzallah K, et al. Seroprevalence of SARS-CoV-2 in the West Bank region of Palestine: a cross-sectional seroepidemiological study. Bmj Open. 2021;11(2): e044552.	Richard A, Wisniak A, Perez-Saez J, Garrison-Desany H, Petrovic D, Piumatti G, et al. Seroprevalence of anti-SARS-CoV-2 IgG antibodies, risk factors for infection and associated symptoms in Geneva, Switzerland: a population-based study [Internet]. 2020 Dec [cited 2022 Jan 20] p. 2020.12.16.20248180. Available from: https://www.medrxiv.org/content/10.1101/2020.12.16.20248180v1	Rosenberg ES, Tesoriero JM, Rosenthal EM, Chung R, Barranco MA, Styer LM, et al. Cumulative incidence and diagnosis of SARS-CoV-2 infection in New York. Ann Epidemiol. août 2020;48:23-29.e4.
LOCATION/ COUNTRY	China (in 4 countries)	West Bank, Palestine	Geneva, Switzerland	New York, in 99 grocery shops in 26 counties
SELECTION CRITERIA	Men and women, all ages	Men and women, all ages	Men and women, 5–94 years old, with asymptomatic cases	Men and women, all ages
TYPE OF POPULATIONS	Suspected patients, confirmed patients and consecutive follow-up patients	Doing housework in the West Bank, people visiting Palestinian medical laboratories	Population of the canton of Geneva were invited to participate in a seroprevalence study, along with household members five years and older (General population)	General population
SAMPLE SIZE	571 were enrolled in the cross-sectional study, including 235 COVID-19 patients and 336 suspected	1,355 from 11 governorates, including 112 locations in the West Bank and 1136 peoples visiting Palestinian medical labs	8,344	15,101
SAMPLING METHOD	Random sampling	Random sampling	Random sampling	Random sampling
SEROPREVALENCE	<u>Between 2.1 and 5.4% positives cases</u>	The random sample of Palestinians living in the West Bank yielded 0% seroprevalence with 95% and an adjusted CI of 0.0043%. seroprevalence with 95% and adjusted CI (0% to 0.0043%), while the laboratory reference samples yielded an estimated seroprevalence of 0.354% with 95% and an adjusted seroprevalence of 0.354% with 95% and an adjusted CI (0.001325% to 0.011566%)	First study months: 7.1% (95% CrI 5.5–8.7) Second months: 9.0% (95% CrI 7.5–10.5) Third months: 7.1% (95% CrI 5.7–8.5)	14% 2.139 positive cases including 300 adults
STUDY PERIOD	January-March 2020	June-2020	6.April-30. June 2020	April-2020
RISK FACTORS			Age, gender, employment status, occupational category, change in work, specific change in work, educational level, single, smocking, BMI category, chronic health condition, risk-contact exposure	

(Continued)

Table 1. (Continued)

NUMBER	1.	2.	3.	4.
SYMPTOMS	Mild symptoms		Fatigue, headache, sneezing/ rhinorrhea, fever, cough, anosmia/disgeusia, myalgia/ arthralgia, sore throat, dyspnea, loss of appetite, diarrhea, abdominal pain, nausea/vomiting, other symptoms, Asymptomatic cases	
NUMBER	73.	74.	75.	76.
REFERENCE	Rostami A., Sepidarkish M., M.G. Leeflang M., Mohammad Riahi S., Nourollahpour Shiadeh M., Esfandiyari S., et al. "SARS-CoV-2 seroprevalence worldwide: a systematic review and meta-analysis". <i>Clinical Microbiology and Infection</i> . 26 Dec 2021. 27 (3):331–340.	Roxhed N, Bendes A, Dale M. A translational multiplex serology approach to profile the prevalence of anti-SARS-CoV-2 antibodies in home-sampled blood . <i>MedRxiv</i> 2020.	Samore MH, Looney A, Orleans B, Greene T, Seegert N, Delgado JC, et al. SARS-CoV-2 seroprevalence and detection fraction in Utah urban populations from a probability- based sample [Internet]. 2020 Oct [cited 2022 Jan 20] p. 2020.10.26.20219907. Available from: https://www.medrxiv.org/ content/10.1101/2020.10.26. 20219907v1	Santarelli A, Lalitsasivimol D, Bartholomew N, Reid S, Reid J, Lyon C, et al. The seroprevalence of SARS-CoV-2 in a rural southwest community . <i>J Osteopath Med</i> . 1 févr 2021;121 (2):199–210.
LOCATION/ COUNTRY	Worldwide	Stockholm, Sweden	Utah, Salt, Lake, Davis, and Summit, United States	Kingman area, Arizona
SELECTION CRITERIA	Men and women all ages	Men and women, 20–74 years old	Men and women, all ages	Men and women, 18 years and over, 380 women, 186 men, 458 white, 303 health professionals
TYPE OF POPULATIONS	General population	General population	General population, population of the four counties included in this serological survey	Community member and health care workers
SAMPLE SIZE	399,265	2,000	8,108, 5,125 household	566 took part in the final analysis
SAMPLING METHOD	Several techniques	Random households in urban Stockholm	Random sampling	Random sampling
SEROPREVALENCE	Between 0.37% to 22.1% positive cases Northern Europe (5.27%) Southern Europe (4.41%) North America (4.41%) Western Europe (3.17%) East Asia (2.02%) South America (1.45%)	10.1–10.8%	The overall prevalence of IgG antibody to SARS-CoV-2 was estimated at 0.8%. The estimated seroprevalence-to-case count ratio was 2.4, corresponding to a detection fraction of 42%	The seroprevalence of SARS-CoV-2 was found to be 8.0% (45 of 566) in the sample
STUDY PERIOD	January-August 2020	April-2020	4.May-30 June 2020	September-October 2020
RISK FACTORS	Ethnicity	Sex, age, flu-like	Location, children's household, gender, age, ethnicity, race, co- morbidities, exposure	
SYMPTOMS		Breathing symptoms	Nasopharyngeal	Anosmia/ageusia, cough, chest congestion, fever, shortness of breath, chest pain
NUMBER	77.	78.	79.	80.
REFERENCE	Satpati PS, Sarangi SS, Gantait KS, Endow S, Mandal NC, Panchanan K, et al. Sero- surveillance (IgG) of SARS-CoV-2 among Asymptomatic General population of Paschim Medinipur, West Bengal, India [Internet]. <i>medRxiv</i> ; 2020 [cited 2022 Feb 9]. p. 2020.09.12.20193219. Available from: https:// www.medrxiv.org/content/10.1101/2020.09.12. 20193219v1	Shakiba M, Nazari SSH, Mehrabian F, Rezvani SM, Ghasempour Z, Heidarzadeh A. Seroprevalence of COVID-19 virus infection in Guilan province, Iran . <i>medRxiv</i> 2020; published online May 1. DOI:10. 1101/2020.04.26.20079244 (preprint).	Sharma N, Sharma P, Basu S, Saxena S, Chawla R, Dushyant K, et al. The seroprevalence and trends of SARS-CoV-2 in Delhi, India: A repeated population- based seroepidemiological study [Internet]. 2020 Dec [cited 2022 Jan 20] p. 2020.12.13.20248123. Available from: https://www. medrxiv.org/content/10.1101/ 2020.12.13.20248123v1	Shaw JA, Meiring M, Cummins T, Chegou NN, Claassen C, Du Plessis N, et al. Higher SARS-CoV-2 seroprevalence in workers with lower socioeconomic status in Cape Town, South Africa . <i>Plos One</i> . 25 févr 2021;16(2):e0247852.

(Continued)

Table 1. (Continued)

NUMBER	1.	2.	3.	4.
LOCATION/ COUNTRY	Paschim Medinipur, West Bengal, India	Guilan, Iran	Delhi, India	South Africa
SELECTION CRITERIA	Men and women, all ages	Men and women, all ages,	Men and women, 5 years old and over	Representation of all strata
TYPE OF POPULATIONS	Asymptomatic general population and RTPCR positive cases in 30 villages or wards of municipalities General population	General population (telephone invitation)	Age ≥ 5 years and residents of Delhi for at least the past six months	The workforce of a popular commercial and tourist complex
SAMPLE SIZE	488	196 households, including 551 subjects	47,470	405 volunteers
SAMPLING METHOD	Random sampling	Random cluster sampling	Multi-stage random sampling	Random sampling
SEROPREVALENCE	Of the 458 asymptomatic general population, 19 asymptomatic people found to be seropositive IgG for SARS-CoV-2 with Mean or average total seropositivity rate of 4.15%. 19 Out of 30 (63.33%) RTPCR positive patients found Seronegative Highest Seropositivity percentage found in Ghatal Municipality of 12.50% followed by Daspur II of 9.78%, Daspur I of 4.00% and Kharagpur Municipality of 3.70% and Midnapur Municipality of 6.25%	22%	A total of 4267 (n = 15046), 4311 (n = 17409), and 3829 (n = 15015) positive tests indicatives of the presence of IgG antibody to SARS-CoV-2 were observed during the August, September, and October 2020 serosurvey rounds, respectively. The adjusted seroprevalence: August: 39% (95% CI 27.65–29.14) September: 24.08% (95% CI 23.43–24.74) October: 24.71% (95% CI 24.01, 25.42%)	96 (23.7%) were positive for SARS-CoV-2 IgG Of those who tested positive 46 (47.9%) reported no symptoms of COVID-19 in the previous 6 months The specificity of the test was 98.54% (95%CI 94.82%-99.82%) in the pre-COVID controls
STUDY PERIOD	July-August 2020	April-2020	August-October 2020	August-September 2020
RISK FACTORS	Gender, age, locatily, slum area, employment, education, statut social, travel history, hydroxychloroquine prophylaxis, migrant labourer, history of chicken pox, influenza vaccination status.		Age, gender, education, household size, income, living in Urban Slum, location	
SYMPTOMS	Asymptomatic cases,	General, respiratory or gastrointestinal symptoms.		New cough, fever or chills, new dyspnoea, sore throat, loss of smell, diarrhoea, nausea and/or vomiting
NUMBER	81.	82.	83.	84.
REFERENCE	Sherman A, Reuben J, David N, Quasie-Woode DP, Gunn JKL, Nielsen CF, et al. SARS-CoV-2 Seroprevalence Survey Among District Residents Presenting for Serologic Testing at Three Community-Based Test Sites—Washington, DC, July–August, 2020 [Internet]. 2021 Feb [cited 2022 Jan 20] p. 2021.02.15.21251764. Available from: https://www.medrxiv.org/content/10.1101/2021.02.15.21251764v1	Silva AAM da, Lima-Neto LG, Azevedo C de MP e S de, Costa LMM da, Bragança MLBM, Filho AKDB, et al. Population-based seroprevalence of SARS-CoV-2 is more than halfway through the herd immunity threshold in the State of Maranhão, Brazil [Internet]. medRxiv; 2020 [cited 2022 Feb 2]. p. 2020.08.28.20180463. Available from: https://www.medrxiv.org/content/10.1101/2020.08.28.20180463v1	Silveira MF, Barros AJD, Horta BL, Pellanda LC, Dellagostin OA, Struchiner CJ, et al. Repeated population-based surveys of antibodies against SARS-CoV-2 in Southern Brazil [Internet]. medRxiv; 2020 [cited 2022 Jan 31]. p. 2020.05.01.20087205. Available from: https://www.medrxiv.org/content/10.1101/2020.05.01.20087205v2	Snoeck CJ, Vaillant M, Abdelrahman T, Satagopam VP, Turner JD, Beaumont K, et al. Prevalence of SARS-CoV-2 infection in the Luxembourgish population—the CON-VINCE study [Internet]. 2020 May [cited 2022 Jan 18] p. 2020.05.11.20092916. Available from: https://www.medrxiv.org/content/10.1101/2020.05.11.20092916v1
LOCATION/ COUNTRY	Washington, DC, United States	State of Moranhao, Brazil	Southern Brazil	Luxembourg
SELECTION CRITERIA	Men and women, 6 years old and over	Men and women, between 1 and over 70 years old, with asymptomatic cases	Household members living in one of the nine sentinel cities in Brazil	Men and women, 18 years old and over
TYPE OF POPULATIONS	DC Residents	A population-based household survey	General population	General population

(Continued)

Table 1. (Continued)

NUMBER	1.	2.	3.	4.
SAMPLE SIZE	508 households and 671 samples	3,156	4,188 in first round 4,500 in the second round	1,862
SAMPLING METHOD	Random sampling	A three-stage cluster sampling stratified by four state regions was used	Multistage sampling to select 50 census tracts with probability proportionate to size in each sentinel city, and 10 households at random in each tract based on census listings updated in 2019 One individual randomly selected through household	Random sampling
SEROPREVALENCE	7.6%.	Seroprevalence of total antibodies against SARS-CoV-2 was 40.4% (95%CI 35.6–45.3)	In the first round: 0.0477%; 95% confidence interval (CI) 0.0058%;0.1724%) In the second round: 0.1333%; 95% CI 0.0489%;0.2900%	IgA: 11.07% (95%CI = [9.54;12.60]) IgG: 2.09% (95%CI = [1.37;2.82])
STUDY PERIOD	27. July-21. August 2020	27. July-8. August 2020	28. Feb- 30. Apr 2020	15. April- 5. May 2020
RISK FACTORS	Ethnicity/Race, age, work	Age, location, ethnicity/race, number of residents, social status	The most densely populated centres were the most affected by COVID-19	/
SYMPTOMS		62.2% had more than three symptoms, 11.1% had one or two symptoms, and 26.0% were asymptomatic We also showed that among the infected, 26.0% were asymptomatic and 11.1% had one or two symptoms and that the predominant symptoms among those who tested positive for SARS-CoV-2 were anosmia/hyposmia (49.5%), ageusia/dysgeusia (47.7%), fever (45.6%), headache (45.4%), myalgia (43.6%), and fatigue (41.1%). The infection fatality rate was 0.17%, higher for males and advanced age groups		
NUMBER	85.	86.	87.	88.
REFERENCE	Snyder T, Ravenhurst J, Cramer EY, Reich NG, Balzer LB, Alfandari D, et al. Serological surveys to estimate cumulative incidence of SARS-CoV-2 infection in adults (Sero-MAss study), Massachusetts, July-August 2020: a mail-based cross-sectional study. MedRxiv Prepr Serv Health Sci. 9 mars 2021;	Sood N, Simon P, Ebner P, Eichner D, Reynolds J, Bendavid E, et al. Seroprevalence of SARS-CoV-2-Specific Antibodies Among Adults in Los Angeles County, California, on April 10–11, 2020. JAMA. 16 juin 2020;323(23):2425-7.	Soriano V, Meiriño R, Corral O, Guallar MP. Severe Acute Respiratory Syndrome Coronavirus 2 Antibodies in Adults in Madrid, Spain. Clin Infect Dis Off Publ Infect Dis Soc Am. 15 mars 2021;72(6):1101-2.	Stout RL, Rigatti SJ. The Silent Pandemic COVID-19 in the Asymptomatic Population [Internet]. 2021 Jan [cited 2022 Jan 20] p. 2020.11.10.20215145. Available from: https://www.medrxiv.org/content/10.1101/2020.11.10.20215145v3
LOCATION/COUNTRY	Massachusetts	Los Angeles County, California	Madrid, Spain	United States
SELECTION CRITERIA	Men and women, 18 years old and over	Men and women, 18 years old and over, 60% female, 55% between 35 and 54 years old, 58% white	Men and women, asymptomatic adults	Life insurance applicants who had blood tests performed as part of life insurance underwriting at Clinical Reference Laboratories
TYPE OF POPULATIONS	Students, professors, librarians and staff of the University of Massachusetts at Amherst, with no previous covid-19 diagnosis, were invited to participate in this study with a member of their household	General population	Population attending the Clinical University of Madrid	Asymptomatic general population
SAMPLE SIZE	762	865	674	126,587

(Continued)

Table 1. (Continued)

NUMBER	1.	2.	3.	4.
SAMPLING METHOD	Random sampling	Random sampling, they used a representative representative property database of the county managed by LRW Group, a market research company to select participants.	Random sampling	One fifth of all samples tested from a pool of life insurance applicants
SEROPREVALENCE	5,3% and 4%	35% out of 865 positive tests i.e. 4.06%	13,80%	May-June, September, and December timeframes: 3.0%, 6.6% and 10.4%, respectively
STUDY PERIOD	July-August 2020	April-2020	April-May 2020	May-December 2020
RISK FACTORS		Age, kids	The most densely populated centres were the most affected by COVID-19	Age
SYMPTOMS		Fever, cough shortness of breath, loss of sense of smell or taste	Mild symptoms, asymptomatic cases	Asymptomatic cases
NUMBER	89.	90.	91.	92.
REFERENCE	Stringhini S, Wisniak A, Piumatti G, Azman AS, Lauer SA, Baysson H, et al. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study. <i>Lancet Lond Engl.</i> 1 août 2020;396(10247):313-9.	Sulcebe G, Ylli A, Cenko F, Kurti-Prifti M. Rapid increase of SARS-CoV-2 seroprevalence during the 2020 pandemic year in the population of the city of Tirana, Albania [Internet]. 2021 Feb [cited 2022 Jan 20] p. 2021.02.18.21251776. Available from: https://www.medrxiv.org/content/10.1101/2021.02.18.21251776v1	Sutton M, Cieslak P, Linder M. Notes from the Field: Seroprevalence Estimates of SARS-CoV-2 Infection in Convenience Sample—Oregon, May 11–June 15, 2020. <i>MMWR Morb Mortal Wkly Rep.</i> 14 août 2020;69(32):1100-1.	Tabanejad Z, Darvish S, Boroujeni ZB, Asadi SS, Mesri M, Raiesi O, et al. Seroepidemiological Study of Novel Corona Virus (CoVID-19) in Tehran, Iran [Internet]. medRxiv; 2021 [cited 2022 Feb 9]. p. 2021.01.18.20248911. Available from: https://www.medrxiv.org/content/10.1101/2021.01.18.20248911v1
LOCATION/COUNTRY	Geneva, Switzerland	city of Tirana, Albania	Oregon, California	Teheran, Iran
SELECTION CRITERIA	Men and women, all ages	Men and women, individuals 20–70 years old	Men and women, 18 years old and over	Men and women, all ages
TYPE OF POPULATIONS	Former participants in the Health Bus study and members of their household	General population (communities)	Sample visiting an ambulatory centre, emergency and hospital between May and June 2020	Patients for Valiasr, Sajad and Ghaem hospitals, Tehran, the capital of Iran
SAMPLE SIZE	2,766samples from 1,339 households	1,081	897	1,375
SAMPLING METHOD	Random sampling	In two rounds using two independently selected samples randomly selected from lists of the inhabitants	Random sampling	Random sampling
SEROPREVALENCE	8–5% in the second week, 10–9% in the third week, 6–6% in the fourth week, and 10–8% in the fifth week	In early July: 7.5% (95% CI: 4.3%-10.7%) Late December 2020: 48.2% (95% CI: 44.8%-51.7%)	1%, 9 positive cases out of 897 samples, 0% seroprevalence in children under 17	Among all participants, 291 patients (21.2%) were positive for either IgM or IgG antibodies, indicating past or present infection (P <0.05)
STUDY PERIOD	April-May 2020	July-December 2020	May-June 2020	April-October 2020
RISK FACTORS				Co-morbidities, gender, age
SYMPTOMS		Reported symptoms		
NUMBER	93.	94.	95.	96.

(Continued)

Table 1. (Continued)

NUMBER	1.	2.	3.	4.
REFERENCE	Takita M, Matsumura T, Yamamoto K, Yamashita E, Hosoda K, Hamaki T, et al. Geographical Profiles of COVID-19 Outbreak in Tokyo: An Analysis of the Primary Care Clinic-Based Point-of-Care Antibody Testing. J Prim Care Community Health. déc 2020;11:2150132720942695.	Tess BH, Granato CFH, Alves MCGP, Pintao MC, Rizzatti E, Nunes MC, et al. SARS-CoV-2 seroprevalence in the municipality of São Paulo, Brazil, ten weeks after the first reported case [Internet]. medRxiv; 2020 [cited 2022 Feb 2]. p. 2020.06.29.20142331. Available from: https://www.medrxiv.org/content/10.1101/2020.06.29.20142331v1	Tsertsvadze T, Gatsrelia L, Mirziashvili M, Dvali N, Abutidze A, Metchurchlishvili R, et al. SARS-CoV-2 antibody seroprevalence in Tbilisi, the capital city of country of Georgia [Internet]. 2020 Sep [cited 2022 Jan 20] p. 2020.09.18.20195024. Available from: https://www.medrxiv.org/content/10.1101/2020.09.18.20195024v1	Velumani A, Nikam C, Suraweera W, Fu SH, Gelband H, Brown P, et al. SARS-CoV-2 Seroprevalence in 12 Cities of India from July-December 2020 [Internet]. medRxiv; 2021 [cited 2022 Jan 31]. p. 2021.03.19.21253429. Available from: https://www.medrxiv.org/content/10.1101/2021.03.19.21253429v1
LOCATION/COUNTRY	Tokyo, Japan	Sao Paulo, Brazil	Tbilisi, Georgia	12 Cities, India
SELECTION CRITERIA	Men and women, all ages	Men and women, 18 years old and over	Men and women, 18–64 years old	People of all ages who underwent testing for SARS-CoV-2 antibodies between June 12, 2020 and December 31, 2020 by Thyrocare Laboratories
TYPE OF POPULATIONS	Asymptomatic patients Patients in the two community clinics in Tokyo (Navitas Clinic Shinjuku and Tachikawa)	A population-based household survey, who are residents of six districts in São Paulo City.	Residents of capital city of Tbilisi	Urban population
SAMPLE SIZE	1,071	517 (299 randomly-selected adults and 218 cohabitants)	1,068	448,518
SAMPLING METHOD	Random sampling, from web publication on the homepage of the clinics	Random sampling	Convenience sampling	Based on geographical areas and laboratories Random sampling
SEROPREVALENCE	4.68% positive cases in Tokyo for 1.83% in the other regions	4.7% (95% CI 3.0–6.6%)	Nine persons tested positive for IgG: crude seroprevalence: 0.84%, (95% CI: 0.33%-1.59%), weighted seroprevalence: 0.94% (95% CI: 0.37%-1.95%), weighted and adjusted for test accuracy: 1.02% (95% CI: 0.38%-2.18%). The seroprevalence estimates translate into 7,200 to 8.800 infections among adult residents of Tbilisi	31% (140,631)
STUDY PERIOD	April-May 2020	May-2020	May-2020	July-December 2020
RISK FACTORS	Illness cohabitation, co-worker, working environment, age, location	Age, gender, race, education,		
SYMPTOMS	Fever, asymptomatic cases	Fever, cough, shortness of breath, sore throat, rhinorrhea, fatigue, myalgia, diarrhea, ageusia, anosmia	Fever, cough, shortness of breath, fatigue, sore throat, rhinorrhea, loss of smell/taste	
NUMBER	97.	98.	99.	100.
REFERENCE	Vena A, Berruti M, Adessi A, Blumetti P, Brignole M, Colognato R, et al. Prevalence of Antibodies to SARS-CoV-2 in Italian Adults and Associated Risk Factors. J Clin Med. 27 août 2020;9(9).	Vodičar PM, Valenčak AO, Zupan B, Županc TA, Kurdiša S, Korva M, et al. Low prevalence of active COVID-19 in Slovenia: a nationwide population study of a probability-based sample. Clin Microbiol Infect. 2020 Nov 1;26 (11):1514–9.	Vu SL, Jones G, Anna F, Rose T, Richard J-B, Bernard-Stoecklin S, et al. Prevalence of SARS-CoV-2 antibodies in France: results from nationwide serological surveillance [Internet]. 2020 Oct [cited 2022 Jan 20] p. 2020.10.20.20213116. Available from: https://www.medrxiv.org/content/10.1101/2020.10.20.20213116v1	Wang X, Gao W, Cui S, Zhang Y, Zheng K, Ke J, et al. A population-based seroprevalence survey of severe acute respiratory syndrome coronavirus 2 infection in Beijing, China [Internet]. medRxiv; 2020 [cited 2022 Feb 9]. p. 2020.09.23.20197756. Available from: https://www.medrxiv.org/content/10.1101/2020.09.23.20197756v1
LOCATION/COUNTRY	In 5 administrative departments of the regions of Liguria and Lombardia in Italy	Slovenia	France	Beijing, China

(Continued)

Table 1. (Continued)

NUMBER	1.	2.	3.	4.
SELECTION CRITERIA	Men and women, 18 years old and over	Men and women, all ages	Men and women, all ages	Men and women, residents who aged > 1 year old
TYPE OF POPULATIONS	A large sample of healthy adult volunteers, not hospitalized	All permanent and temporary residents of Slovenia	French on the national territory and people who are living in Guadeloupe, Martinique, Mayotte, French Guiana, La Réunion	General population (Residents)
SAMPLE SIZE	3,609	1,368	11,021	2,184
SAMPLING METHOD	Random sampling	Random sampling	Random sampling	Multi-stage cluster random sampling
SEROPREVALENCE	An average seroprevalence of 11% with 9.2% of men, 12.5% of women and 13.5% of the over-55s That is 398 positive cases out of 3609	Two of 1366 participants tested positive for SARS-CoV-2 RNA (prevalence 0.15%; posterior mean 0.18%, 95% Bayesian confidence interval 0.03e0.47; 95% highest density region (HDR) 0.01e0.41)	Mid-March: 0.41% [0.05–0.88] Mid-April: 4.14% [3.31–4.99] Mid-May: 4.93% [4.02–5.89]	The seroprevalence of COVID-19 in Beijing was estimated < 0.17%
STUDY PERIOD	March-April 2020	March-October 2020	March-May 2020	April 2020
RISK FACTORS			Age, location	
SYMPTOMS	Influenza-like illness or loss of sense of smell or taste were	Acute respiratory symptoms and/or fever		Mild symptoms
NUMBER	101	102	103	104
REFERENCE	Ward H, Cooke G, Atchison C, Whitaker M, Elliott J, Moshe M, et al. Declining prevalence of antibody positivity to SARS-CoV-2: a community study of 365,000 adults [Internet]. 2020 Oct [cited 2022 Jan 20] p. 2020.10.26.20219725. Available from: https://www.medrxiv.org/content/10.1101/2020.10.26.20219725v1	Ward H, Atchison C, Whitaker M, Ainslie KE, Elliott J, Okell L, et al. Antibody prevalence for SARS-CoV-2 following the peak of the pandemic in England: REACT2 study in 100,000 adults [Internet]. 2020 Aug [cited 2022 Jan 20] p. 2020.08.12.20173690. Available from: https://www.medrxiv.org/content/10.1101/2020.08.12.20173690v2	Waterfield T, Watson C, Moore R, Ferris K, Tonry C, Watt AP, et al. Seroprevalence of SARS-CoV-2 antibodies in children—A prospective multicentre cohort study [Internet]. 2020 Sep [cited 2022 Jan 20] p. 2020.08.31.20183095. Available from: https://www.medrxiv.org/content/10.1101/2020.08.31.20183095v1	Weis S, Scherag A, Baier M, Kiehnopf M, Kamradt T, Kolanos S, et al. Seroprevalence of SARS-CoV-2 antibodies in an entirely PCR-sampled and quarantined community after a COVID-19 outbreak—the CoNAN study. medRxiv 2020; published online July 17. DOI:10.1101/2020.07.15.20154112 (preprint).
LOCATION/COUNTRY	United Kingdom, England	England	5 United Kingdom sites (Belfast, Cardiff, Manchester, Glasgow and London)	Neustadt-am-Rennsteig, Germany
SELECTION CRITERIA	Men and women, 18 years old and over	Men and women, 18 years and over	Men and women, 2–15 years old	Men and women, all ages,
TYPE OF POPULATIONS	Adult population of England (General population)	General population (representative sample)	Children of healthcare workers	All households in the community of Neustadt-am-Rennsteig were informed (by mail prior) General population
SAMPLE SIZE	99,908, 105,829 and 159,367	109,076	992	626
SAMPLING METHOD	Random sampling	Random sampling	Random sampling	Random sampling
SEROPREVALENCE	Antibody prevalence, adjusted for test characteristics and weighted to the adult population of England, declined from 6.0% [5.8, 6.1], to 4.8% [4.7, 5.0] and 4.4% [4.3, 4.5], a fall of 26.5% [-29.0, -23.8] over the three months of the study. There was a decline between rounds 1 and 3 in all age groups, with the highest prevalence of a positive result and smallest overall decline in positivity in the youngest age group (18–24 years: -14.9% [-21.6, -8.1]), and lowest prevalence and largest decline in the oldest group (75+ years: -39.0% [-50.8, -27.2]) The decline from rounds 1 to 3 was largest in those who did not report a history of COVID19, (-64.0% [-75.6, -52.3]), compared to -22.3% ([-27.0, -17.7]) in those with SARS-CoV-2 infection confirmed on PCR	Adjusted and re-weighted: 6.0% (95% CI: 5.8, 6.1)	There were 68 (6.9%) participants with positive SARS-CoV-2 antibody tests indicative of previous SARS-CoV-2 infection Belfast had significantly lower seroprevalence than all other sites at 0.9% (95% CI 0.2 to 3.3, n = 215)	Only 8-4% of the tested population were seropositive for anti-SARS-CoV-2 antibodies in which 6-2% (38/610) had proven SARS-CoV-2 infection, indicating 22 a low rate of asymptomatic cases
STUDY PERIOD	June-September 2020	20. June-13. July 2020	16. April-3. July 2020	May-2020

(Continued)

Table 1. (Continued)

NUMBER	1.	2.	3.	4.
RISK FACTORS	Location, age, gender, employment, household size, population density	Employment (Health and care home worker), ethnicity, age, smoking status (no smokers), household size and deprivation quintile (more deprived areas or living in larger households), BMI (overweight or obese), region, symptoms severity and contact with case (having more severe symptoms, and having contact with a confirmed or suspected case)	Known household, the role of the parent, contact with a household member	
SYMPTOMS	No symptoms, atypical symptoms only, screening symptoms	Severe symptoms	Fever 21/68 (31%), gastrointestinal symptoms (diarrhoea, vomiting and abdominal cramps) 13/68 (19%) and headache 12/68 (18%). The presence of fever, cough or changes in a sense of smell/taste were recorded in 26/68 (38%) of participants	
NUMBER	105	106	107	108
REFERENCE	Wells PM, Doores KM, Couvreur S. Estimates of the rate of infection and asymptomatic COVID-19 disease in a population sample from se England. MedRxiv 2020.	Wiens, Kirsten W, and al. “Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Juba, South Sudan: a population-based study”. medRxiv. 2021.doi:10.1101/2021.03.08.21253009	Williamson JC, Wierzba TF, Santacatterina M, Munawar I, Seals AL, Ballard CAP, et al. Analysis of Accumulated SARS-CoV-2 Seroconversion in North Carolina: The COVID-19 Community Research Partnership [Internet]. 2021 Mar [cited 2022 Jan 20] p. 2021.03.11.21253226. Available from: https://www.medrxiv.org/content/10.1101/2021.03.11.21253226v1	Zejda JE, Brożek GM, Kowalska M, Barański K, Kaleta-Pilarska A, Nowakowski A, et al. Seroprevalence of Anti-SARS-CoV-2 Antibodies in a Random Sample of Inhabitants of the Katowice Region, Poland. Int J Environ Res Public Health. 19 mars 2021;18(6).
LOCATION/COUNTRY	England	Juba, South Sudan	North California, United States	Katowice, Poland
SELECTION CRITERIA	Men and women, 19–86 years old with asymptomatic cases	Men and women, all ages	Men and women, 18 years old and over	Men and women, all ages
TYPE OF POPULATIONS	General population	General population	Adult community residents (General population)	General population
SAMPLE SIZE	431	2,214	17,688	1,167
SAMPLING METHOD	Random sampling	Random sampling	Random sampling	Random sampling
SEROPREVALENCE	12%	22.3% had anti-SRAS-CoV-2 IgG titers above the levels of the pre-malignant samples	The average number of serology test results submitted per participant was 3.0 (±1.9). At December 20, 2020, the overall probability of seropositivity in the CCRP population was 32.6%. At February 15, 2021 the probability among non-healthcare workers was 49%	The prevalence of IgG seropositivity was 11.4% (95% CI 9.5–13.2%). (95% CI: 9.5–13.2%) and IgM seropositivity was 4.6 (95% CI: 3.5–5.8%).
STUDY PERIOD	March-June 2020	August-September 2020	April 2020-February 2021	March-November 2020
RISK FACTORS				
SYMPTOMS	Asympatomatic cases, neither fever, persistent cough, nor anosmia			Fever, chills fatigue, cough, clogged nose, dyspnea/trouble breathing, headache, nausea and loss of smell/taste
NUMBER	109	110	111	112

(Continued)

Table 1. (Continued)

NUMBER	1.	2.	3.	4.
REFERENCE	Adetifa IMO, Uyoga S, Gitonga JN, Mugo D, Otiende M, Nyagwange J, et al. Temporal trends of SARS-CoV-2 seroprevalence in transfusion blood donors during the first wave of the COVID-19 epidemic in Kenya [Internet]. 2021 Feb [cited 2022 Jan 20] p. 2021.02.09.21251404. Available from: https://www.medrxiv.org/content/10.1101/2021.02.09.21251404v1	Alandijany TA, El-Kafrawy SA, Al-Ghamdi AA, Qashqari FS, Faizo AA, Tolah AM, et al. Lack of Antibodies to SARS-CoV-2 among Blood Donors during COVID-19 Lockdown: A Study from Saudi Arabia . <i>Healthcare</i> . Janv 2021;9(1):51.	Amorim Filho L, Szwarcwald CL, Mateos S de OG, Leon ACMP de, Medronho R de A, Veloso VG, et al. Seroprevalence of anti-SARS-CoV-2 among blood donors in Rio de Janeiro, Brazil . <i>Rev Saude Publica</i> . 2020;54:69.	Bendavid E, Mulaney B, Sood N, Shah S, Bromley-Dulfano R, Lai C, et al. COVID-19 antibody seroprevalence in Santa Clara County, California . <i>Int J Epidemiol</i> . 22 févr 2021;
LOCATION/COUNTRY	Kenya, Africa	Saudi Arabia	Rio de Janeiro, Brazil	Santa Clara County, California
SELECTION CRITERIA	Men and women, aged 16–65 years, weighing ≥50kg, with haemoglobin of 12–5g/dl, a normal blood pressure (systolic 120–129 mmHg and diastolic BP of 80–89 mmHg), a pulse rate of 60–100 beats per minute and without any history of illness in the past 6 months.	Men and women, all ages	All Voluntary blood donors of the Hemorio, Brazil	Individual who could be tested (obtain blood or blood clotted), living in Santa Clara County and tests results matched with personal data
TYPE OF POPULATIONS	Blood donors	Healthy blood donors attending one of the largest hospitals in the western region of Saudi Arabia	Voluntary blood donors	Adults and children (county resident)
SAMPLE SIZE	9,922	956	2,857	3,330
SAMPLING METHOD	Random sampling	Random sampling	Volunteers and adjusted for sex and age group Random sampling	Using Facebook ads targeting a sample of individuals living within the county by demographic and geographic characteristics
SEROPREVALENCE	Period 1: 30. April-19. June = the adjusted seroprevalence of SARS-CoV-2 was 5.2% (95% CI 3.7–6.7%). Period 2: 20. June-19. August = it had risen to 9.1% (95% CI 7.2–11.3%) Period 3: 20. August-30. September = it was maintained at 9.1% (95% CI 7.6–10.8%)	14 positive cases out of 956 i.e. 0.27%	Unadjusted 4.0% (95% CI: 3.3–4.7), weighted by Rio de Janeiro State Population 3.8% (95% CI: 3.1–4.5)	Raw prevalence: 1.5% (exact binomial 95CI 1.1–2.0%)
STUDY PERIOD	April-September 2020	January-May 2020	14.April-27, April 2020	3. April-4. April 2020
RISK FACTORS	Age, sex and residence characteristics	Tabagism	Period of blood collection, age, level of education	The most densely populated centres were the most affected by COVID-19 Age, Young people (between 18–30 years old), low level of education
SYMPTOMS				Fever, cough, shortness of breath, runny nose, sore throat, loss of smell, loss of taste, no symptoms
NUMBER	113	114	115	116
REFERENCE	Buss LF, Prete CA, Abraham CM, Mendrone A, Salomon T, Almeida-Neto C de, et al. COVID-19 herd immunity in the Brazilian Amazon [Internet]. <i>medRxiv</i> ; 2020 [cited 2022 Feb 9]. p. 2020.09.16.20194787. Available from: https://www.medrxiv.org/content/10.1101/2020.09.16.20194787v1	Chang L, Hou W, Zhao L, Zhang Y, Wang Y, Wu L, et al. The prevalence of antibodies to SARS-CoV-2 among blood donors in China [Internet]. 2020 Jul [cited 2022 Jan 18] p. 2020.07.13.20153106. Available from: https://www.medrxiv.org/content/10.1101/2020.07.13.20153106v1	Davis G, York AJ, Bacon WC, Suh-Chin L, McNeal MM, Yarawsky AE, et al. Seroprevalence of SARS-CoV-2 Infection in Cincinnati Ohio USA from August to December 2020 [Internet]. 2021 Mar [cited 2022 Jan 20] p. 2021.03.11.21253263. Available from: https://www.medrxiv.org/content/10.1101/2021.03.11.21253263v1	Dopico XC, Muschiol S, Christian M, Hanke L, Sheward DJ, Grinberg NF, et al. Seropositivity in blood donors and pregnant women during the first year of SARS-CoV-2 transmission in Stockholm, Sweden [Internet]. <i>medRxiv</i> ; 2021 [cited 2022 Jan 31]. p. 2020.12.24.20248821. Available from: https://www.medrxiv.org/content/10.1101/2020.12.24.20248821v2
LOCATION/COUNTRY	Brazilian Amazon	Wuhan, Shenzhen and Shijiazhuang, China	Cincinnati Ohio, USA	Stockholm, Sweden

(Continued)

Table 1. (Continued)

NUMBER	1.	2.	3.	4.
SELECTION CRITERIA	Men and women, blood donors living in Manaus or Sao Paulo.	Men and women, all blood donors living in Wuhan, Shenzhen, and Shijiazhuang	Men and women, volunteers and healthy unique blood donors presenting to the Hoxworth Blood Center	Men and women, asymptomatic blood donors and pregnant women
TYPE OF POPULATIONS	Blood donors	Healthy blood donors	Healthy blood donors	Healthy blood donors
SAMPLE SIZE	1,000	38,144	9,550	5,100
SAMPLING METHOD	Based on geographical areas Random sampling	Random sampling (all blood donors who lived in one of the three cities were enrolled in the study)	Random sampling	Random sampling
SEROPREVALENCE	In June: 44%	2.29% (407/17,794, 95%CI: 2.08% to 2.52%) in Wuhan, 0.029% (2/6,810, 95%CI: 0.0081% to 0.11%) in Shenzhen, and 0.0074% (1/13,540, 95%CI: 0.0013% to 0.042%) in Shijiazhuang	8.40%	19.2% (95% Bayesian CI [15.1–24.4]) at the end of February 2021
STUDY PERIOD	February-August 2020	January-April 2020	August-December 2020	14. March 2020-February 2021
RISK FACTORS		Period of blood donation, female and older age	Age, regions	
SYMPTOMS				Asymptomatic cases
NUMBER	117	118	119	120
REFERENCE	Erikstrup C, Hother CE, Pedersen OBV, Mølbak K, Skov RL, Holm DK, et al. Estimation of SARS-CoV-2 infection fatality rate by real-time antibody screening of blood donors [Internet]. medRxiv; 2020 [cited 2022 Feb 9]. p. 2020.04.24.20075291. Available from: https://www.medrxiv.org/content/10.1101/2020.04.24.20075291v1	Fiore JR, Centra M, De Carlo A, Granato T, Rosa A, Sarno M, et al. FAR AWAY FROM HERD IMMUNITY TO SARS-CoV-2: results from a survey in healthy blood donors in South Eastern Italy [Internet]. Infectious Diseases (except HIV/AIDS); 2020 Jun [cited 2022 Jan 18]. Available from: http://medrxiv.org/lookup/doi/10.1101/2020.06.17.20133678	Fischer B, Knabbe C, Vollmer T. SARS-CoV-2 IgG seroprevalence in blood donors located in three different federal states, Germany, March to June 2020. Euro Surveill Bull Eur Sur Mal Transm Eur Commun Dis Bull. juill 2020;25(28).	Gallian P, Pastorino B, Morel P, Chiaroni J, Ninove L, de Lamballerie X. Lower prevalence of antibodies neutralizing SARS-CoV-2 in group O French blood donors. Antiviral Res. sept 2020;181:104880.
LOCATION/COUNTRY	Denmark	Apulia region, South Eastern Italy	Three federal states, German	France
SELECTION CRITERIA	Men and women, danish blood donors aged 17–69 years giving blood between April 6 to 17 2020	Men and women, apparently healthy subjects, 18–65 years old	Men and women, all ages	Men and women, all ages, asymptomatic or paucisymptomatic SARS-CoV-2 cases
TYPE OF POPULATIONS	Blood donors	Healthy blood donors	Regular blood donors	Blood donors
SAMPLE SIZE	9,496	904	3,186	998
SAMPLING METHOD	First donors were included Random sampling	Random sampling	Random sampling	Random sampling
SEROPREVALENCE	Combined adjusted: 1.7% (CI: 0.9–2.3)	0.99% (9/304)	IgG seroprevalence was 0.91% (95% confidence interval (CI): 0.58–1.24) overall, ranging from 0.66% (95% CI: 0.13–1.19) in Hesse to 1.22% (95% CI: 0.33–2.10) in Lower Saxony	2.82% for men and 2.69% for women. 1.32% for group O compared to 3.86% for the other groups
STUDY PERIOD	6.April-17. April 2020	1. May-31. May 2020	March-June 2020	April-May 2020
RISK FACTORS	The most densely populated centres were the most affected by COVID-19 Age, kids, presence of an seropositiv case in the household, region		Presence of an seropositiv case in the household	The most densely populated centres were the most affected by COVID-19 Age, young people (between 18–30 years old)

(Continued)

Table 1. (Continued)

NUMBER	1.	2.	3.	4.
SYMPTOMS			Fever, leucocyte count	Asymptomatic or pauci-symptomatic SARS-CoV-2 infections
NUMBER	121	122	123	124
REFERENCE	Germain N, Herwegh S, Hatzfeld A-S, Bocket L, Prevost B, Danze P-M, et al. Retrospective study of COVID-19 seroprevalence among tissue donors at the onset of the outbreak before implementation of strict lockdown measures in France. Cell Tissue Bank.	Gidding HF, Machalek DA, Hendry AJ, Quinn HE, Vette K, Beard FH, et al. Seroprevalence of SARS-CoV-2-specific antibodies in Sydney after the first epidemic wave of 2020. Med J Aust. mars 2021;214(4):179-85.	Jin DK, Nesbitt DJ, Yang J, Chen H, Horowitz J, Jones M, et al. Seroprevalence of Anti-SARS-CoV-2 Antibodies in a Cohort of New York City Metro Blood Donors using Multiple SARS-CoV-2 Serological Assays: Implications for Controlling the Epidemic and “Reopening” [Internet]. 2020 Nov [cited 2022 Jan 20] p. 2020.11.06.20220087. Available from: https://www.medrxiv.org/content/10.1101/2020.11.06.20220087v1	Kamath K, Baum-Jones E, Jordan G, Haynes W, Waitz R, Shon J, et al. Prevalence of antibodies to SARS-CoV-2 in healthy blood donors in New York [Internet]. 2020 Oct [cited 2022 Jan 20] p. 2020.10.19.20215368. Available from: https://www.medrxiv.org/content/10.1101/2020.10.19.20215368v1
LOCATION/COUNTRY	France	Sydney	New-York City	New-York, United States
SELECTION CRITERIA	Men and women, all ages	Men and women, all ages Pregnant women aged 20–39, Australian between 20 and 69	Men and women, 16–78 years old	Men and women, 17–80 years old, with asymptomatic cases
TYPE OF POPULATIONS	A tissue donor population	They had provided blood for testing in some of the diagnose pathology departments.	Blood donors	Healthy blood donors
SAMPLE SIZE	235 donors	5,339	1,000	1,559
SAMPLING METHOD	Random sampling	Random sampling	Random sampling	Random sampling
SEROPREVALENCE	1,7% positives cases	Thirty-eight of 5339 specimens were IgG-positive (general pathology, 19 of 3231; prenatal screening, 7 of 560; plasmapheresis donors, 12 of 1548)The adjusted seroprevalence estimate among those with general pathology blood tests (all ages) was 0.15% and 0.29% and 0.29% for plasmapheresis donors (20–69 years). In people aged 20–39 years, the common age group for all three collection groups, the adjusted seroprevalence estimate was 0.24% for the general pathology group, 0.79% for the prenatal screening group, and 0.69% for the plasmapheresis donors. Overall the seroprevalence is estimated to be less than 1%	13.7% positivity	With SERA (Serum Epitope Repertoire Analysis), we observed a significant increase in SARS-CoV-2 seropositivity rates over the four-month period, from 0% [95% CI: 0–1.5%] in March to 11.6% [6.0–21.2%] in July
STUDY PERIOD	November 2019-March 2020	April-June 2020	June-July 2020	March-July 2020
RISK FACTORS	Age, young people (between 18–30 years old)			Age, gender, race
SYMPTOMS	Respiratory distress (23 donors), dyspnea (14 donors), other flu-like/respiratory symptoms (18 donors), chest CT image opacity without clinical symptoms (2 donors), cough (1 donor), fever (1 donor).			Asymptomatic cases, mild symptoms
NUMBER	125	126	127	128

(Continued)

Table 1. (Continued)

NUMBER	1.	2.	3.	4.
REFERENCE	Mahallawi WH, Al-Zalabani AH. The seroprevalence of SARS-CoV-2 IgG antibodies among asymptomatic blood donors in Saudi Arabia. Saudi J Biol Sci. mars 2021;28(3):1697-701.	Martinez-Acuña N, Avalos-Nolazco D, Rodriguez-Rodriguez D, Martinez-Liu C, Taméz RC, Flores-Arechiga A, et al. Seroprevalence of anti-SARS-COV-2 antibodies in blood donors from Nuevo Leon state, Mexico, during the beginning of the COVID-19 pandemic [Internet]. 2020 Nov [cited 2022 Jan 20] p. 2020.11.28.20240325. Available from: https://www.medrxiv.org/content/10.1101/2020.11.28.20240325v1	Ng D, Goldgof G, Shy B, Levine A, Balcerek J, Bapat SP, et al. SARS-CoV-2 seroprevalence and neutralizing activity in donor and patient blood from the San Francisco Bay Area. medRxiv 2020; published online May 27. DOI:10.1101/2020.05.19.20107482 (preprint).	Ojal J, Brand SPC, Were V, Okiro EA, Kombe IK, Mburu C, et al. Revealing the extent of the COVID-19 pandemic in Kenya based on serological and PCR-test data [Internet]. medRxiv; 2020 [cited 2022 Feb 9]. p. 2020.09.02.20186817. Available from: https://www.medrxiv.org/content/10.1101/2020.09.02.20186817v1
LOCATION/COUNTRY	Saudi Arabia	Nuevo Leon state, Mexico	San Francisco Bay Area	Kenya, Africa
SELECTION CRITERIA	Men and women, all ages	Men and women, blood donors living in Nuevo Leon state who attended two donation venues. Donors selected according to the requirements of the Mexican Official Norm NOM-253-SSA1-2012	Men and women, 18 years old and over	Men and women, all ages
TYPE OF POPULATIONS	Asymptomatic Blood donors	Blood donors	Blood donors	Residents, blood donors
SAMPLE SIZE	1,212donors	1,968	2,000	320,000
SAMPLING METHOD	Random sampling	Based on geographic areas and blood bank center Random sampling	Random sampling	Random sampling
SEROPREVALENCE	The seroprevalence of SARS-CoV-2 among blood donors in donors in Al-Madinah was 19.31% (n = 234/1212). (n = 234/1212)	3.99%	Seropositivity 0.1% in 1,000 blood donors	5.2%-41%
STUDY PERIOD	May-July 2020	1. January- 30. August 2020	March 2020	February-July 2020
RISK FACTORS		Age		
SYMPTOMS	Asymptomatic cases			
NUMBER	129	130	131	132
REFERENCE	Percivalle E, Cambiè G, Cassaniti I, Nepita EV, Maserati R, Ferrari A, et al. Prevalence of SARS-CoV-2 specific neutralising antibodies in blood donors from the Lodi Red Zone in Lombardy, Italy, as at 06 April 2020. Euro Surveill Bull Eur Sur Mal Transm Eur Commun Dis Bull. juin 2020;25(24).	Saeed S, Drews SJ, Pambrun C, Yi Q-L, Osmond L, O'Brien SF. SARS-CoV-2 seroprevalence among blood donors after the first COVID-19 wave in Canada. Transfusion (Paris). mars 2021;61(3):862-72.	Slot E, Hogema BM, Reusken CBEM, Reimerink JH, Molier M, Karregat JHM, et al. Herd immunity is not a realistic exit strategy during a COVID-19 outbreak [Internet]. 2022 [cited 2022 Jan 18]. Available from: https://www.researchsquare.com/article/rs-25862/v1	Sughayer MA, Mansour A, Nuirat AA, Souan L, Ghanem M, Siag M, et al. Dramatic Rise of Seroprevalence Rates of SARS-CoV-2 Antibodies among Healthy Blood Donors: The evolution of a Pandemic [Internet]. 2021 Mar [cited 2022 Jan 20] p. 2021.03.02.21252448. Available from: https://www.medrxiv.org/content/10.1101/2021.03.02.21252448v1
LOCATION/COUNTRY	Lodi Red Zone, Italy (10 municipalities)	Canada	Netherlands	Jordan
SELECTION CRITERIA	272 Men, 118 Women, 19–70 years old, median age 46 years	Men and women, 18 years old and over	Men and women, be completely healthy at the time of donation, 18 years old and over	Healthy asymptomatic subjects between the ages of 18 and 63 who underwent routine screening to determine their acceptability for donation. With asymptomatic cases

(Continued)

Table 1. (Continued)

NUMBER	1.	2.	3.	4.
TYPE OF POPULATIONS	Registered blood donors, with asymptomatic cases	Blood donors throughout the country	Blood plasma donors and convalescent plasma donors	Healthy blood donors
SAMPLE SIZE	390	74,642 donors	7,361	1,374
SAMPLING METHOD	Random sampling	Random sampling	By Age, gender, and zip code of the subject's residence Random sampling	Three batches based on period of sampling
SEROPREVALENCE	20 positive cases of 390 5.13%	Blood donors nationwide 552/74642 donors had detectable antibodies, the adjusted seroprevalence was 7.0/1000 (0.7%) donors. Prevalence was differential by geography Ontario had the highest rate at 8.8/1000 donors, compared to the Atlantic region at 4.5/1000 donors; adjusted odds ratio (aOR) 2.2. Donors who self-identified as an ethnic minority donors were more likely than white donors to be seroreactive a OR 1.5	3.1% (230/7361)	January to september 2020: 0% (95% CI 0.00%, 0.51%) (two first groups) Late January and early February 2020: 27.4% (95% CI 22.5% and 32.9%) (third group)
STUDY PERIOD	April-2020	May-July2020	1. April-15. April 2020	January 2020-February 2021
RISK FACTORS	The most densely populated centres were the most affected by COVID-19		Age (aged 18–30 years)	
SYMPTOMS	Fever, fatigue, cough, cold sore throat, anosmia and dysgeusia, muscular pain, diarrhoea, asymptomatic cases		Mild symptoms	Asymptomatic cases
NUMBER	133	134	135	136
REFERENCE	Sykes W, Mhlanga L, Swanevelder R, Glatt TN, Grebe E, Coleman C, et al. Prevalence of anti-SARS-CoV-2 antibodies among blood donors in Northern Cape, KwaZulu-Natal, Eastern Cape, and Free State provinces of South Africa in January 2021. Res Sq. 12 févr 2021;	Thompson CP, Grayson NE, Paton RS, Bolton JS, Lourenço J, Penman BS, et al. Detection of neutralising antibodies to SARS-CoV-2 to determine population exposure in Scottish blood donors between March and May 2020. Eurosurveillance. 2020 Oct 22;25(42):2000685.	Uyoga S, Adetifa IMO, Karanja HK, Nyagwange J, Tuju J, Wanjiku P, et al. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Kenyan blood donors [Internet]. 2020 Jul [cited 2022 Jan 20] p. 2020.07.27.20162693. Available from: https://www.medrxiv.org/content/10.1101/2020.07.27.20162693v1	Valenti L, Bergna A, Pelusi S, Facciotti F, Lai A, Tarkowski M, et al. SARS-CoV-2 seroprevalence trends in healthy blood donors during the COVID-19 Milan outbreak [Internet]. 2020 May [cited 2022 Jan 20] p. 2020.05.11.20098442. Available from: https://www.medrxiv.org/content/10.1101/2020.05.11.20098442v2
LOCATION/COUNTRY	The Northern Cape, provinces, KwaZulu-Natal, Eastern Cape and the Free State, South Africa	Scotland	Kenyan, Africa	Milan, Northern Italy
SELECTION CRITERIA	Men and women, 15–69 years old	Men and women, 16 years old and over	Blood donors aged 16–65 years, weighing \geq 50kg, with haemoglobin of 12.5g/dl, a normal blood pressure (systolic 120–129 mmHg and diastolic BP of 80–89 mmHg), a pulse rate of 60–100 beats per minute and without any history of illness in the past 6 months	Healthy asymptomatic adults aged 18–70 years old
TYPE OF POPULATIONS	Blood donors	Blood donors	Blood donors	Blood donors
SAMPLE SIZE	4,858 donors	3,500	3,098	789
SAMPLING METHOD	Random sampling	Based on geographical areas (region) and period. Random sampling	Random sampling	Random sampling

(Continued)

Table 1. (Continued)

NUMBER	1.	2.	3.	4.
SEROPREVALENCE	EC-63% (2.8%), NC-32% (2.2%), FS-46% (2.4%) and ZN-52% (2.4%) with Eastern Cape (EC), Free State (FS), KwaZulu Natal (ZN) and Northern Cape (NC)	3,17% (111/3500)	Crude overall seroprevalence: 5.6% (174/3098) Population-weighted, test- adjusted national seroprevalence: 5.2% (95% CI 3.7–7.1%)	Overall adjusted: 2.7%, 95% c.i. 0.3–6%
STUDY PERIOD	January-2020	March-May 2020	30. April- 16. June 2020	24. February-8. April 2020
RISK FACTORS		Geographical areas, health board	Region, age	Age, rate of triglycerides, eosinophils, and lymphocytes
SYMPTOMS				Asymptomatic cases
NUMBER	137	138	139	
REFERENCE	Vassallo RR, Bravo MD, Dumont LJ, Hazegh K, Kamel H. Seroprevalence of Antibodies to SARS-CoV-2 in US Blood Donors [Internet]. 2020 Sep [cited 2022 Jan 20] p. 2020.09.17.20195131. Available from: https:// www.medrxiv.org/content/10.1101/2020.09.17. 20195131v1	Villarreal A, Rangel G, Zhang X, Wong D, Britton G, Fernandez PL, et al. Performance of a Point of Care Test for Detecting IgM and IgG Antibodies Against SARS-CoV-2 and Seroprevalence in Blood Donors and Health Care Workers in Panama. <i>Front Med.</i> 2 mars 2021;8:616106.	Younas A, Waheed S, Khawaja S, Imam M, Borhany M, Shamsi T. Seroprevalence of SARS-CoV-2 antibodies among healthy blood donors in Karachi, Pakistan. <i>Transfus Apher Sci Off J World Apher Assoc Off J Eur Soc Haemapheresis.</i> déc 2020;59 (6):102923.	
LOCATION/ COUNTRY	United States	Panama	Karachi, Pakistan	
SELECTION CRITERIA	Men and women, 18–64 years old	Men and women, 18 years old and over	Only men, 30–37 years old	
TYPE OF POPULATIONS	Blood donors	Blood donors and health workers (healthy volunteer)	Healthy blood donors who are venaked to the National Institute for Blood and Bone Marrow Transplantation between May June and July 2020. But also those who came in October 2019	
SAMPLE SIZE	252,882	702	380 donors	
SAMPLING METHOD	Random sampling	Random sampling	Random sampling	
SEROPREVALENCE	Unique donors (n = 252,882) showed an overall seroprevalence in June (1.37%) and July (2.26%), with the highest prevalence in northern New Jersey (7.3%)	97.2% (95%CI 84.2–100.0%) to detect both IgM and IgG. The analysis showed a Kappa of 0.898 (95%CI 0.811–0.985) and 0.918 (95%CI 0.839–0.997) for IgM and IgG, respectively We found an overall antibody seroprevalence of 11.6% (95% CI 8.5–15.8%) health care workers and healthy blood donors	40%	
STUDY PERIOD	1. June-31. July 2020	April-July 2020	June-2020	
RISK FACTORS	Gender, age, race/ethnicity, education level, collection site types, location			
SYMPTOMS			Mild symptoms	

<https://doi.org/10.1371/journal.pone.0269104.t001>

Serological status

The determination of seroprevalence in most studies involved the ELISA test, which detects IgG and IgM antibodies. Other studies used a serum epitope repertoire analysis or a plaque

reduction neutralization test, and IgA antibodies were also identified. Estimated seroprevalence was 0 to 69% (Table 1). Among the 133 original studies, 13 studies investigated IgG [11–23], 8 studies IgG or IgM [24–31], two studies IgG and IgM [32,33], one study IgA or IgG [34], one study IgG only or IgG and IgM [35] and one study IgG or IgM or both simultaneously [36].

Prevalence by continent and over time

General population. The most-represented and explored territories were Europe, with 34 studies, distributed among Italy (9), France (4), England (4), Spain (3), Germany (3), Slovenia (2), Switzerland (2), Luxembourg (1), Austria (1), Hungary (1), Denmark (1), Faroe Island (1), Greece (1), Albania (1), Sweden (1), United Kingdom (1), Georgia (1), Poland (1), and Estonia (1); the United States, with 24 studies; other Organisation for Economic Co-operation and Development (OECD) countries, with Japan (3), Canada (1), and Australia (1); and other countries, with India (12), Brazil (6), China (6), Iran (4), Argentina (1), Iraq (1), Palestine (1), Pakistan (1), Qatar (1), South Africa (1), and Sudan (1). Fig 2 represents the spread of seroprevalence estimates in each continent over the study period.

Most studies ($n = 52$) estimated a seroprevalence of SARS-CoV-2 of 0 to 7%; for more than half, the seroprevalence was $< 5\%$. England had the highest seroprevalence, estimated at 69% from July to September 2020, followed by Iraq, at 62.6% between July 2020 and February 2021.

Blood donors. The most represented and explored territories were Europe, with 10 studies, distributed among Italy (3), France (2), Germany (1), Denmark (1), Netherlands (1), Sweden (1), and Scotland (1); the United States, with 7 studies; other OECD countries, with Canada (1), Australia (1) and Mexico (1); and other countries, with Kenya (3), Brazil (2), Saudi Arabia (2), China (1), South Africa (1), Pakistan (1), and Panama (1).

Most studies ($n = 20$) estimated a seroprevalence of SARS-CoV-2 of 0 to 7%; for more than half, the seroprevalence was $< 5\%$ ($n = 17$).

South Africa had the highest seroprevalence, estimated at 63% in January 2021, and the lowest seroprevalence was estimated in the United States, 0% in March 2020.

Symptoms. A total of 84 articles [3,4,13,15,16,18,21,23,29,31,32,35,37–108] focused on COVID-19-related symptoms. The seroprevalence of asymptomatic cases ranged from 0%




Fig 2. Seroprevalence (%) in each continent over the observation period.

<https://doi.org/10.1371/journal.pone.0269104.g002>

(Q1-Q3 1–3%) to 31.5% (3–7%). Only 35 articles explicitly assessed asymptomatic populations [18,19,24–26,32,45,47,53,56,59,64,66,69,75,76,78,81,83,89,90,92,93,95,98,99,102,105–114]. The symptoms most strongly associated with seropositivity were anosmia, ageusia, fever, fatigue, rhinorrhea, sore throat, breathing difficulties, flu-like symptoms, cough, dyspnoea, myalgias, headache and asthenia. Diarrhoea, muscle aches, and chest pain were also common.

Risk factors. The most densely populated centres were the most affected by COVID-19 [8,16,20,32,40,41,48,50,53,55,56,59,71,76,78,81,86,87,88,91,92,94,95,101,102,106,115–126]. Sex was examined in 14 studies, which found mostly no significant difference (one a higher seroprevalence in men and 6 a higher seroprevalence in women).

In articles published by the end of 2020 [91,95,99,118], the age group most significantly affected was young adults aged 18–30 years. Other studies showed an increase in seroprevalence in older age groups. For children, eighteen studies [37,47,49,56,60,68,75,79,83,85,88,89,93,108,119,122,127,128] showed significantly lower seroprevalence than for adults. For articles published after late 2020, the age ranges were narrower than in articles published at the beginning of the pandemic. Since the emergence of the virus, young populations have also been found to have high seroprevalence and should not be overlooked [40,96]. The impact of social disadvantage was documented in the general population and blood donors in a comparison of seroprevalence according to income [32,47,68,104,126,129–134] or education level [18,19,20,47,48,53,57,68,82,99,130–138]. Prevalence was higher in the lowest than highest income groups (prevalence doubled [32], from 1.8% to 3.7%). The seroprevalence was two times higher with low than high education [91]. Thirteen studies showed that the risk of seropositivity increased by about 30% with a confirmed COVID-19 case in the household [23,32,36,47,55,59,68,75,79,88,92,125,136]. Ten studies showed that the risk of seropositivity increased with the number of children in the household [16,25,55,71,77,88,116,120,125,133]. The highest seroprevalence was found in the most deprived areas [59,67,68,86,92,104,126,130–133,139,140]. Finally, seven studies [18,60,68,87,93,116,141] found a decrease in SARS-CoV-2 seroprevalence associated with greater frequency of smoking.

Discussion

Published studies of seroprevalence of SARS-CoV-2 in the general population over the year after the onset of the pandemic up to early April 2021 showed estimates ranging from 0% in Palestine in the West Bank between June and July 2020 to 69% in England between July and September 2020, with different dynamics across continents.

This review purposely focused on the first year of the pandemic to better understand the spread and dynamics from the early stages of the pandemic and to summarize identified factors for SARS-CoV-2 penetration that could further serve as a reference for adapted measures to mitigate future epidemics. Such measures include barriers, social distancing, evolving vaccines according to the molecular and biological monitoring of viruses, and preventive or early treatments to avoid severity.

Fig 2 shows that the blood donors were not fully representative of the general population. Their seroprevalence and respective peaks show variations of lower magnitude in general. Blood donors could have been an early resource for documenting the epidemic before their decrease in frequency, with population-based studies taking place later. Some continents have fewer donors than others, probably related to national health care organisation.

The variations observed across studies, besides the true virus exposure and spread differences over space and time within countries, could be due to different sampling techniques and

the use of different serological tests. Our results suggest that the number of symptomatic cases was lower than the number of actual cases, despite only few studies ($n = 21$) characterizing asymptomatic seropositive cases.

Most of the studies did not find or found minimal differences regarding sex. Age categories analysis did not yet reveal any conclusive results. Social disadvantage seemed to play a role, at least for the least well-off categories, but the impact of belonging to the most privileged categories, whatever the classification used, remains to be elucidated. Finally, the presence of a COVID-19 case in a household increasing the risk of the other members has been demonstrated consistently for developing antibodies.

This review had a longer study period than six previous reviews; it focused on general populations and blood donors; it covered a larger world area by including all continents as compared with Grant et al. [8], Rostami et al. [10], Chen et al. [6] and Levesque and Maybury [9], and it summarised a number of risk factors identified, mostly of a sociodemographic nature.

A limitation of this scoping review is the heterogeneity of samples with different age ranges, so seroprevalence data are not fully comparable. Potential biases in such seroprevalence observational studies also do not account for SARS-CoV-2-related deaths. Also, we did not include grey literature because we did not know how to search such literature in the particular context of this pandemic with so much suspicion of non-peer-reviewed publications. A third limitation is that we did not assess the methodological quality of the studies reviewed. Finally, the results of seroprevalence studies may have been affected by the specificity and sensitivity of different serological methods used.

In conclusion, from this scoping review of seroprevalence studies over the first year of the COVID-19 pandemic, the seroprevalence of SARS-CoV-2 varied according to the study period, with lower seroprevalence at the beginning of the epidemic than between July and September 2020. This review documented the progression of this virus across the world in time and space and the risk factors that influenced its spread.

Supporting information

S1 Checklist. PRISMA-ScR.
(DOCX)

Author Contributions

Conceptualization: H  l  ne Jeulin, Anne Gegout-Petit, Evelyne Schvoerer, Francis Guillemin.

Data curation: Cl  mentine Metzger, Taylor Leroy, Agathe Bochnakian.

Resources: Taylor Leroy, Francis Guillemin.

Supervision: Francis Guillemin.

Writing – original draft: Cl  mentine Metzger.

Writing – review & editing: Taylor Leroy, Agathe Bochnakian, H  l  ne Jeulin, Anne Gegout-Petit, Karine Legrand, Evelyne Schvoerer, Francis Guillemin.

References

1. Coronavirus: chiffres cl  s et   volution de la COVID-19 en France et dans le Monde [Internet]. [cited 2021 May 8]. Available from: /dossiers/coronavirus-covid-19/coronavirus-chiffres-cles-et-evolution-de-la-covid-19-en-france-et-dans-le-monde.

2. WHO-2019-nCoV-Seroepidemiology-2020.2-eng.pdf [Internet]. [cited 2021 May 4]. Available from: <https://apps.who.int/iris/bitstream/handle/10665/332188/WHO-2019-nCoV-Seroepidemiology-2020.2-eng.pdf?sequence=1&isAllowed=y>.
3. Vena A, Berruti M, Adessi A, Blumetti P, Brignole M, Colognato R, et al. Prevalence of Antibodies to SARS-CoV-2 in Italian Adults and Associated Risk Factors. *J Clin Med*. 2020 Aug 27; 9(9). <https://doi.org/10.3390/jcm9092780> PMID: 32867328
4. Fiore JR, Centra M, De Carlo A, Granato T, Rosa A, Sarno M, et al. Results from a survey in healthy blood donors in South Eastern Italy indicate that we are far away from herd immunity to SARS-CoV-2. *J Med Virol*. 2021 Mar; 93(3):1739–42. <https://doi.org/10.1002/jmv.26425> PMID: 32790086
5. Bobrovitz N, Arora RK, Cao C, Boucher E, Liu M, Donnici C, et al. Global seroprevalence of SARS-CoV-2 antibodies: A systematic review and meta-analysis. *PLoS One*. 2021; 16(6):e0252617. <https://doi.org/10.1371/journal.pone.0252617> PMID: 34161316
6. Chen X, Chen Z, Azman AS, Deng X, Sun R, Zhao Z, et al. Serological evidence of human infection with SARS-CoV-2: a systematic review and meta-analysis. *Lancet Glob Health*. 2021 May; 9(5):e598–609. [https://doi.org/10.1016/S2214-109X\(21\)00026-7](https://doi.org/10.1016/S2214-109X(21)00026-7) PMID: 33705690
7. Franceschi VB, Santos AS, Glaeser AB, Paiz JC, Caldana GD, Lessa CLM, et al. Population-based prevalence surveys during the COVID-19 pandemic: a systematic review [Internet]. medRxiv; 2020 [cited 2022 Feb 9]. p. 2020.10.20.20216259. Available from: <https://www.medrxiv.org/content/10.1101/2020.10.20.20216259v1>. <https://doi.org/10.1002/rmv.2200> PMID: 34260777
8. Grant R, Dub T, Andrianou X, Nohynek H, Wilder-Smith A, Pezzotti P, et al. SARS-CoV-2 population-based seroprevalence studies in Europe: a scoping review. *BMJ Open*. 2021 Apr 1; 11(4):e045425. <https://doi.org/10.1136/bmjopen-2020-045425> PMID: 33795310
9. Levesque J, Maybury DW. A note on COVID-19 seroprevalence studies: a meta-analysis using hierarchical modelling [Internet]. 2020 May [cited 2022 Jan 14] p. 2020.05.03.20089201. Available from: <https://www.medrxiv.org/content/10.1101/2020.05.03.20089201v1>.
10. Rostami A, Sepidarkish M, Leeflang MMG, Riahi SM, Nourollahpour Shiadeh M, Esfandyari S, et al. SARS-CoV-2 seroprevalence worldwide: a systematic review and meta-analysis. *Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis*. 2021 Mar; 27(3):331–40. <https://doi.org/10.1016/j.cmi.2020.10.020> PMID: 33228974
11. Arnold CRK, Srinivasan S, Herzog CM, Gontu A, Bharti N, Small M, et al. SARS-CoV-2 Seroprevalence in a University Community: A Longitudinal Study of the Impact of Student Return to Campus on Infection Risk Among Community Members. *MedRxiv Prepr Serv Health Sci*. 2021 Feb 19.
12. Babu GR, Sundaresan R, Athreya S, Akhtar J, Pandey PK, Maroor PS, et al. The burden of active infection and anti-SARS-CoV-2 IgG antibodies in the general population: Results from a statewide survey in Karnataka, India [Internet]. medRxiv; 2020 [cited 2023 Mar 9]. p. 2020.12.04.20243949. Available from: <https://www.medrxiv.org/content/10.1101/2020.12.04.20243949v1>.
13. Bogogiannidou Z, Vontas A, Dadouli K, Kyritsi MA, Soteriades S, Nikoulis DJ, et al. Repeated leftover serosurvey of SARS-CoV-2 IgG antibodies, Greece, March and April 2020. *Euro Surveill Bull Eur Sur Mal Transm Eur Commun Dis Bull*. 2020 Aug; 25(31). <https://doi.org/10.2807/1560-7917.ES.2020.25.31.2001369> PMID: 32762796
14. George CE, Inbaraj LR, Chandrasingh S, de Witte LP. High seroprevalence of COVID-19 infection in a large slum in South India; what does it tell us about managing a pandemic and beyond? *Epidemiol Infect*. 2021 Feb 4; 149:e39. <https://doi.org/10.1017/S0950268821000273> PMID: 33536108
15. Murhekar MV, Bhatnagar T, Selvaraju S, Saravanakumar V, Thangaraj JWV, Shah N, et al. SARS-CoV-2 antibody seroprevalence in India, August–September, 2020: findings from the second nationwide household serosurvey. *Lancet Glob Health*. 2021 Mar; 9(3):e257–66. [https://doi.org/10.1016/S2214-109X\(20\)30544-1](https://doi.org/10.1016/S2214-109X(20)30544-1) PMID: 33515512
16. Nawa N, Kuramochi J, Sonoda S, Yamaoka Y, Nukui Y, Miyazaki Y, et al. Seroprevalence of SARS-CoV-2 IgG Antibodies in Utsunomiya City, Greater Tokyo, after first pandemic in 2020 (U-CORONA): a household- and population-based study [Internet]. 2020 Jul [cited 2022 Jan 20] p. 2020.07.20.20155945. Available from: <https://www.medrxiv.org/content/10.1101/2020.07.20.20155945v1>.
17. Pérez-Olmeda M, Saugar JM, Fernández-García A, Pérez-Gómez B, Pollán M, Avellón A, et al. Evolution of antibodies against SARS-CoV-2 over seven months: experience of the Nationwide Seroprevalence ENE-COVID Study in Spain [Internet]. 2021 Mar [cited 2022 Jan 20] p. 2021.03.11.21253142. Available from: <https://www.medrxiv.org/content/10.1101/2021.03.11.21253142v1>.
18. Richard A, Wisniak A, Perez-Saez J, Garrison-Desany H, Petrovic D, Piumatti G, et al. Seroprevalence of anti-SARS-CoV-2 IgG antibodies, risk factors for infection and associated symptoms in Geneva, Switzerland: a population-based study [Internet]. 2020 Dec [cited 2022 Jan 20]

- p. 2020.12.16.20248180. Available from: <https://www.medrxiv.org/content/10.1101/2020.12.16.20248180v1>.
19. Satpati PS, Sarangi SS, Gantait KS, Endow S, Mandal NC, Panchanan K, et al. Sero-surveillance (IgG) of SARS-CoV-2 among Asymptomatic General population of Paschim Medinipur, West Bengal, India [Internet]. medRxiv; 2020 [cited 2022 Feb 9]. p. 2020.09.12.20193219. Available from: <https://www.medrxiv.org/content/10.1101/2020.09.12.20193219v1>.
 20. Sharma N, Sharma P, Basu S, Saxena S, Chawla R, Dushyant K, et al. The seroprevalence and trends of SARS-CoV-2 in Delhi, India: A repeated population-based seroepidemiological study [Internet]. 2020 Dec [cited 2022 Jan 20] p. 2020.12.13.20248123. Available from: <https://www.medrxiv.org/content/10.1101/2020.12.13.20248123v1>.
 21. Tsertsvadze T, Gatsrelia L, Mirziashvili M, Dvali N, Abutidze A, Metchurchlishvili R, et al. SARS-CoV-2 antibody seroprevalence in Tbilisi, the capital city of country of Georgia [Internet]. 2020 Sep [cited 2022 Jan 20] p. 2020.09.18.20195024. Available from: <https://www.medrxiv.org/content/10.1101/2020.09.18.20195024v1>.
 22. Wiens KE, Mawien PN, Rumunu J, Slater D, Jones FK, Moheed S, et al. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Juba, South Sudan: a population-based study [Internet]. 2021 Mar [cited 2022 Jan 20] p. 2021.03.08.21253009. Available from: <https://www.medrxiv.org/content/10.1101/2021.03.08.21253009v1>.
 23. Fischer B, Knabbe C, Vollmer T. SARS-CoV-2 IgG seroprevalence in blood donors located in three different federal states, Germany, March to June 2020. *Euro Surveill Bull Eur Sur Mal Transm Eur Commun Dis Bull*. 2020 Jul; 25(28).
 24. Borges LP, Martins AF, de Melo MS, de Oliveira MGB, Neto JM de R, Dósea MB, et al. Seroprevalence of SARS-CoV-2 IgM and IgG antibodies in an asymptomatic population in Sergipe, Brazil. *Rev Panam Salud Publica Pan Am J Public Health*. 2020; 44:e108.
 25. Duan S, Zhou M, Zhang W, Shen J, Qi R, Qin X, et al. Seroprevalence and asymptomatic carrier status of SARS-CoV-2 in Wuhan City and other places of China. *PLoS Negl Trop Dis*. 2021 Jan; 15(1): e0008975. <https://doi.org/10.1371/journal.pntd.0008975> PMID: 33411805
 26. Ling R, Yu Y, He J, Zhang J, Xu S, Sun R, et al. Seroprevalence and epidemiological characteristics of immunoglobulin M and G antibodies against SARS-CoV-2 in asymptomatic people in Wuhan, China: a cross-sectional study [Internet]. 2020 Aug [cited 2022 Jan 20] p. 2020.06.16.20132423. Available from: <https://www.medrxiv.org/content/10.1101/2020.06.16.20132423v3>.
 27. Pan Y, Li X, Yang G, Fan J, Tang Y, Hong X, et al. Seroprevalence of SARS-CoV-2 immunoglobulin antibodies in Wuhan, China: part of the city-wide massive testing campaign. *Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis*. 2021 Feb; 27(2):253–7. <https://doi.org/10.1016/j.cmi.2020.09.044> PMID: 33035672
 28. Polvere I, Parrella A, Casamassa G, D'Andrea S, Tizzano A, Cardinale G, et al. Seroprevalence of Anti-SARS-CoV-2 IgG and IgM among Adults over 65 Years Old in the South of Italy. *Diagn Basel Switz*. 2021 Mar 9; 11(3). <https://doi.org/10.3390/diagnostics11030483> PMID: 33803299
 29. Qin X, Shen J, Dai E, Li H, Tang G, Zhang L, et al. The seroprevalence and kinetics of IgM and IgG in the progression of COVID-19. *BMC Immunol*. 2021 Feb 17; 22(1):14. <https://doi.org/10.1186/s12865-021-00404-0> PMID: 33596826
 30. Tabanejad Z, Darvish S, Boroujeni ZB, Asadi SS, Mesri M, Raiesi O, et al. Seroepidemiological Study of Novel Corona Virus (CoVID-19) in Tehran, Iran [Internet]. medRxiv; 2021 [cited 2022 Feb 9]. p. 2021.01.18.20248911. Available from: <https://www.medrxiv.org/content/10.1101/2021.01.18.20248911v1>.
 31. Zejda JE, Brożek GM, Kowalska M, Barański K, Kaleta-Pilarska A, Nowakowski A, et al. Seroprevalence of Anti-SARS-CoV-2 Antibodies in a Random Sample of Inhabitants of the Katowice Region, Poland. *Int J Environ Res Public Health*. 2021 Mar 19; 18(6).
 32. Naranbhai V, Chang CC, Beltran WFG, Miller TE, Astudillo MG, Villalba JA, et al. High Seroprevalence of Anti-SARS-CoV-2 Antibodies in Chelsea, Massachusetts. *J Infect Dis*. 2020 Nov 13; 222(12):1955–9. <https://doi.org/10.1093/infdis/jiaa579> PMID: 32906151
 33. Villarreal A, Rangel G, Zhang X, Wong D, Britton G, Fernandez PL, et al. Performance of a Point of Care Test for Detecting IgM and IgG Antibodies Against SARS-CoV-2 and Seroprevalence in Blood Donors and Health Care Workers in Panama. *Front Med*. 2021; 8:616106. <https://doi.org/10.3389/fmed.2021.616106> PMID: 33748157
 34. Snoeck CJ, Vaillant M, Abdelrahman T, Satagopam VP, Turner JD, Beaumont K, et al. Prevalence of SARS-CoV-2 infection in the Luxembourgish population—the CON-VINCE study [Internet]. 2020 May [cited 2022 Jan 20] p. 2020.05.11.20092916. Available from: <https://www.medrxiv.org/content/10.1101/2020.05.11.20092916v1>.

35. Della Valle P, Fabbri M, Madotto F, Ferrara P, Cozzolino P, Calabretto E, et al. Occupational Exposure in the Lombardy Region (Italy) to SARS-CoV-2 Infection: Results from the MUSTANG-OCCUPATION-COVID-19 Study. *Int J Environ Res Public Health*. 2021 Mar 4; 18(5):2567. <https://doi.org/10.3390/ijerph18052567> PMID: 33806578
36. Javed W, Baqar JB, Abidi SHB, Farooq W. Sero-prevalence Findings from Metropolises in Pakistan: Implications for Assessing COVID-19 Prevalence and Case-fatality within a Dense, Urban Working Population [Internet]. *medRxiv*; 2020 [cited 2022 Feb 9]. p. 2020.08.13.20173914. Available from: <https://www.medrxiv.org/content/10.1101/2020.08.13.20173914v1>.
37. Appa A, Takahashi S, Rodriguez-Barraquer I, Chamie G, Sawyer A, Duarte E, et al. Universal PCR and antibody testing demonstrate little to no transmission of SARS-CoV-2 in a rural community. *MedRxiv Prepr Serv Health Sci*. 2020 Aug 17.
38. Alessi D, Borré S, Barale A, Isabella A, Milano F, Rossi MA, et al. [Seroprevalence of anti-SARS-CoV-2 IgG/IgM antibodies in Borgosesia (Piedmont Region, Northern Italy) population: a surveillance strategy in post-lockdown period?]. *Epidemiol Prev*. 2020 Dec; 44(5–6 Suppl 2):200–6.
39. Aziz NA, Corman VM, Echterhoff AKC, Richter A, Schmandke A, Schmidt ML, et al. Seroprevalence and correlates of SARS-CoV-2 neutralizing antibodies: Results from a population-based study in Bonn, Germany [Internet]. 2020 Aug [cited 2022 Jan 20] p. 2020.08.24.20181206. Available from: <https://www.medrxiv.org/content/10.1101/2020.08.24.20181206v1>.
40. Bajema KL, Wiegand RE, Cuffe K, Patel SV, Iachan R, Lim T, et al. Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020. *JAMA Intern Med*. 2021 Apr 1; 181(4):450–60. <https://doi.org/10.1001/jamainternmed.2020.7976> PMID: 33231628
41. Biggs HM, Harris JB, Breakwell L, Dahlgren FS, Abedi GR, Szablewski CM, et al. Estimated Community Seroprevalence of SARS-CoV-2 Antibodies—Two Georgia Counties, April 28–May 3, 2020. *MMWR Morb Mortal Wkly Rep*. 2020 Jul 24; 69(29):965–70. <https://doi.org/10.15585/mmwr.mm6929e2> PMID: 32701941
42. Doi A, Iwata K, Kuroda H, Hasuike T, Nasu S, Kanda A, et al. Seroprevalence of novel coronavirus disease (COVID-19) in Kobe, Japan [Internet]. 2020 May [cited 2022 Jan 14] p. 2020.04.26.20079822. Available from: <https://www.medrxiv.org/content/10.1101/2020.04.26.20079822v2>.
43. Gégout Petit A, Jeulin H, Legrand K, Jay N, Bochnakian A, Vallois P, et al. Seroprevalence of SARS-CoV-2, Symptom Profiles and Sero-Neutralization in a Suburban Area, France. *Viruses*. 2021 Jun 4; 13(6):1076. <https://doi.org/10.3390/v13061076> PMID: 34200070
44. Havers FP, Reed C, Lim T, Montgomery JM, Klena JD, Hall AJ, et al. Seroprevalence of Antibodies to SARS-CoV-2 in 10 Sites in the United States, March 23–May 12, 2020. *JAMA Intern Med*. 2020 Jul 21. <https://doi.org/10.1001/jamainternmed.2020.4130> PMID: 32692365
45. He Z, Ren L, Yang J, Guo L, Feng L, Ma C, et al. Seroprevalence and humoral immune durability of anti-SARS-CoV-2 antibodies in Wuhan, China: a longitudinal, population-level, cross-sectional study. *Lancet Lond Engl*. 2021 Mar 20; 397(10279):1075–84.
46. Hussein NR, Balatay AA, Naqid IA, Jamal SA, Rasheed NA, Ahmed AN, et al. COVID-19 antibody seroprevalence in Duhok, Kurdistan Region, Iraq: A population-based study [Internet]. *medRxiv*; 2021 [cited 2022 Feb 9]. p. 2021.03.23.21254169. Available from: <https://www.medrxiv.org/content/10.1101/2021.03.23.21254169v1>.
47. Inbaraj LR, George CE, Chandrasingh S. Seroprevalence of COVID-19 infection in a rural district of South India: A population-based seroepidemiological study. *PloS One*. 2021; 16(3):e0249247. <https://doi.org/10.1371/journal.pone.0249247> PMID: 33788873
48. Investigators A to beat coronavirus/Action pour battre le coronavirus (Ab CS, Jha P. COVID Seroprevalence, Symptoms and Mortality During the First Wave of SARS-CoV-2 in Canada [Internet]. 2021 Mar [cited 2022 Jan 20] p. 2021.03.04.21252540. Available from: <https://www.medrxiv.org/content/10.1101/2021.03.04.21252540v1>.
49. Investigators RS, Riley S, Ainslie KEC, Eales O, Jeffrey B, Walters CE, et al. Community prevalence of SARS-CoV-2 virus in England during May 2020: REACT study [Internet]. *medRxiv*; 2020 [cited 2022 Feb 2]. p. 2020.07.10.20150524. Available from: <https://www.medrxiv.org/content/10.1101/2020.07.10.20150524v1>.
50. Jögi P, Soeorg H, Ingerainen D, Soots M, Lättekivi F, Naaber P, et al. Seroprevalence of SARS-CoV-2 IgG antibodies in two regions of Estonia (KoroSero-EST-1) [Internet]. 2020 Oct [cited 2022 Jan 20] p. 2020.10.21.20216820. Available from: <https://www.medrxiv.org/content/10.1101/2020.10.21.20216820v1>.
51. Khalagi K, Gharibzadeh S, Khalili D, Mansournia MA, Samiee SM, Aghamohamadi S, et al. Prevalence of COVID-19 in Iran: Results of the first survey of the Iranian COVID-19 Serological Surveillance program [Internet]. *medRxiv*; 2021 [cited 2022 Feb 9]. p. 2021.03.12.21253442. Available from: <https://www.medrxiv.org/content/10.1101/2021.03.12.21253442v2>.

52. Kshatri JS, Bhattacharya D, Kanungo S, Giri S, Palo SK, Parai D, et al. Findings from serological surveys (in August 2020) to assess the exposure of adult population to SARS Cov-2 infection in three cities of Odisha, India [Internet]. medRxiv; 2020 [cited 2022 Feb 9]. p. 2020.10.11.20210807. Available from: <https://www.medrxiv.org/content/10.1101/2020.10.11.20210807v1>.
53. Ladage D, Höglinger Y, Ladage D, Adler C, Yalcin I, Braun RJ. SARS-CoV-2 antibody prevalence and symptoms in a local Austrian population [Internet]. 2020 Nov [cited 2022 Jan 20] p. 2020.11.03.20219121. Available from: <https://www.medrxiv.org/content/10.1101/2020.11.03.20219121v1>.
54. Lavezzo E, Franchin E, Ciavarella C, Cuomo-Dannenburg G, Barzon L, Del Vecchio C, et al. Suppression of a SARS-CoV-2 outbreak in the Italian municipality of Vo'. *Nature*. 2020 Aug; 584(7821):425–9.
55. Levorson RE, Christian E, Hunter B, Sayal J, Sun J, Bruce SA, et al. SARS-CoV-2 Seroepidemiology in Children and Adolescents [Internet]. 2021 Jan [cited 2022 Jan 20] p. 2021.01.28.21250466. Available from: <https://www.medrxiv.org/content/10.1101/2021.01.28.21250466v1>.
56. Lim T, Delorey M, Bestul N, Johannsen M, Reed C, Hall AJ, et al. Changes in SARS CoV-2 Seroprevalence Over Time in Ten Sites in the United States, March—August, 2020. *Clin Infect Dis Off Publ Infect Dis Soc Am*. 2021 Feb 26.
57. McLaughlin CC, Doll MK, Morrison KT, McLaughlin WL, O'Connor T, Sholukh AM, et al. High Community SARS-CoV-2 Antibody Seroprevalence in a Ski Resort Community, Blaine County, Idaho, US. Preliminary Results. *MedRxiv Prepr Serv Health Sci*. 2020 Jul 21.
58. Melotti R, Scaggiante F, Falciani M, Weichenberger CX, Foco L, Lombardo S, et al. Prevalence and determinants of serum antibodies to SARS-CoV-2 in the general population of the Gardena valley. *Epidemiol Infect*. 2021 Aug 3; 149:e194. <https://doi.org/10.1017/S0950268821001886> PMID: 34645534
59. Menachemi N, Yiannoutsos CT, Dixon BE, Duszynski TJ, Fadel WF, Woos-Kaloustian KK, et al. Population Point Prevalence of SARS-CoV-2 Infection Based on a Statewide Random Sample—Indiana, April 25–29, 2020. *MMWR Morb Mortal Wkly Rep*. 2020 Jul 24; 69(29):960–4. <https://doi.org/10.15585/mmwr.mm6929e1> PMID: 32701938
60. Merkely B, Szabó AJ, Kosztin A, Berényi E, Sebestyén A, Lengyel C, et al. Novel coronavirus epidemic in the Hungarian population, a cross-sectional nationwide survey to support the exit policy in Hungary. *GeroScience*. 2020 Aug; 42(4):1063–74. <https://doi.org/10.1007/s11357-020-00226-9> PMID: 32677025
61. Murhekar MV, Bhatnagar T, Selvaraju S, Rade K, Saravanakumar V, Vivian Thangaraj JW, et al. Prevalence of SARS-CoV-2 infection in India: Findings from the national serosurvey, May–June 2020. *Indian J Med Res*. 2020 Aug; 152(1 & 2):48–60. https://doi.org/10.4103/ijmr.IJMR_3290_20 PMID: 32952144
62. Naushin S, Sardana V, Ujjainiya R, Bhatheja N, Kutum R, Bhaskar AK, et al. Insights from a Pan India Sero-Epidemiological survey (Phenome-India Cohort) for SARS-CoV-2 [Internet]. 2021 Feb [cited 2022 Jan 14] p. 2021.01.12.21249713. Available from: <https://www.medrxiv.org/content/10.1101/2021.01.12.21249713v2>.
63. Pagani G, Conti F, Giacomelli A, Bernacchia D, Rondanin R, Prina A, et al. Seroprevalence of SARS-CoV-2 significantly varies with age: preliminary results from a mass population screening [Internet]. 2020 Aug [cited 2022 Jan 20] p. 2020.06.24.20138875. Available from: <https://www.medrxiv.org/content/10.1101/2020.06.24.20138875v2>.
64. Petersen MS, Strøm M, Christiansen DH, Fjallsbak JP, Eliassen EH, Johansen M, et al. Seroprevalence of SARS-CoV-2-Specific Antibodies, Faroe Islands. *Emerg Infect Dis*. 2020 Nov; 26(11):2761–3. <https://doi.org/10.3201/eid2611.202736> PMID: 32726200
65. Poljak M, Valenčak AO, Štrumbelj E, Vodičar PM, Vehovar V, Rus KR, et al. Seroprevalence of SARS-CoV-2 in Slovenia: results of two rounds of a nationwide population study on a probability-based sample, challenges and lessons learned. *Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis*. 2021 Apr 7.
66. Pollán M, Pérez-Gómez B, Pastor-Barriuso R, Oteo J, Hernán MA, Pérez-Olmeda M, et al. Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study. *Lancet Lond Engl*. 2020 Aug 22; 396(10250):535–44. [https://doi.org/10.1016/S0140-6736\(20\)31483-5](https://doi.org/10.1016/S0140-6736(20)31483-5) PMID: 32645347
67. Poustchi H, Darvishian M, Mohammadi Z, Shayanrad A, Delavari A, Bahadorimonfared A, et al. SARS-CoV-2 antibody seroprevalence in the general population and high-risk occupational groups across 18 cities in Iran: a population-based cross-sectional study. *Lancet Infect Dis*. 2021 Apr; 21(4):473–81. [https://doi.org/10.1016/S1473-3099\(20\)30858-6](https://doi.org/10.1016/S1473-3099(20)30858-6) PMID: 33338441
68. Pritsch M, Radon K, Bakuli A, Le Gleut R, Olbrich L, Guggenbühl Noller JM, et al. Prevalence and Risk Factors of Infection in the Representative COVID-19 Cohort Munich. *Int J Environ Res Public Health*. 2021 Mar 30;18(7). <https://doi.org/10.3390/ijerph18073572> PMID: 33808249

69. Qutob N, Awartani F, Salah Z, Asia M, Abu Khader I, Herzallah K, et al. Seroprevalence of SARS-CoV-2 in the West Bank region of Palestine: a cross-sectional seroepidemiological study. *BMJ Open*. 2021 Feb 4; 11(2):e044552. <https://doi.org/10.1136/bmjopen-2020-044552> PMID: 33542045
70. Roxhed N, Bendes A, Dale M, Mattsson C, Hanke L, Dodig-Crnkovic T, et al. A translational multiplex serology approach to profile the prevalence of anti-SARS-CoV-2 antibodies in home-sampled blood [Internet]. 2020 Jul [cited 2022 Jan 13] p. 2020.07.01.20143966. Available from: <https://www.medrxiv.org/content/10.1101/2020.07.01.20143966v1>.
71. Samore MH, Looney A, Orleans B, Greene T, Seeger N, Delgado JC, et al. SARS-CoV-2 seroprevalence and detection fraction in Utah urban populations from a probability-based sample [Internet]. 2020 Oct [cited 2022 Jan 20] p. 2020.10.26.20219907. Available from: <https://www.medrxiv.org/content/10.1101/2020.10.26.20219907v1>.
72. Santarelli A, Lalitsasivimol D, Bartholomew N, Reid S, Reid J, Lyon C, et al. The seroprevalence of SARS-CoV-2 in a rural southwest community. *J Osteopath Med*. 2021 Feb 1; 121(2):199–210.
73. Shakiba M, Nazari SSH, Mehrabian F, Rezvani SM, Ghasempour Z, Heidarzadeh A. Seroprevalence of COVID-19 virus infection in Guilan province, Iran [Internet]. 2020 May [cited 2022 Jan 14] p. 2020.04.26.20079244. Available from: <https://www.medrxiv.org/content/10.1101/2020.04.26.20079244v1>.
74. Shaw JA, Meiring M, Cummins T, Chegou NN, Claassen C, Du Plessis N, et al. Higher SARS-CoV-2 seroprevalence in workers with lower socioeconomic status in Cape Town, South Africa. *PloS One*. 2021; 16(2):e0247852. <https://doi.org/10.1371/journal.pone.0247852> PMID: 33630977
75. Sherman A, Reuben J, David N, Quasie-Woode DP, Gunn JKL, Nielsen CF, et al. SARS-CoV-2 Seroprevalence Survey Among District Residents Presenting for Serologic Testing at Three Community-Based Test Sites—Washington, DC, July–August, 2020 [Internet]. 2021 Feb [cited 2022 Jan 20] p. 2021.02.15.21251764. Available from: <https://www.medrxiv.org/content/10.1101/2021.02.15.21251764v1>.
76. Silva AAM da Lima-Neto LG, Azevedo C de MP e S de, Costa LMM, Bragança MLBM, Filho AKDB, et al. Population-based seroprevalence of SARS-CoV-2 is more than halfway through the herd immunity threshold in the State of Maranhão, Brazil [Internet]. *medRxiv*; 2020 [cited 2022 Feb 2]. p. 2020.08.28.20180463. Available from: <https://www.medrxiv.org/content/10.1101/2020.08.28.20180463v1>.
77. Sood N, Simon P, Ebner P, Eichner D, Reynolds J, Bendavid E, et al. Seroprevalence of SARS-CoV-2-Specific Antibodies Among Adults in Los Angeles County, California, on April 10–11, 2020. *JAMA*. 2020 Jun 16; 323(23):2425–7. <https://doi.org/10.1001/jama.2020.8279> PMID: 32421144
78. Soriano V, Meiriño R, Corral O, Guallar MP. Severe Acute Respiratory Syndrome Coronavirus 2 Antibodies in Adults in Madrid, Spain. *Clin Infect Dis Off Publ Infect Dis Soc Am*. 2021 Mar 15; 72(6):1101–2.
79. Stringhini S, Wisniak A, Piumatti G, Azman AS, Lauer SA, Baysson H, et al. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study. *Lancet Lond Engl*. 2020 Aug 1; 396(10247):313–9. [https://doi.org/10.1016/S0140-6736\(20\)31304-0](https://doi.org/10.1016/S0140-6736(20)31304-0) PMID: 32534626
80. Sulcebe G, Ylli A, Cenko F, Kurti-Prifti M. Rapid increase of SARS-CoV-2 seroprevalence during the 2020 pandemic year in the population of the city of Tirana, Albania [Internet]. 2021 Feb [cited 2022 Jan 20] p. 2021.02.18.21251776. Available from: <https://www.medrxiv.org/content/10.1101/2021.02.18.21251776v1>.
81. Takita M, Matsumura T, Yamamoto K, Yamashita E, Hosoda K, Hamaki T, et al. Geographical Profiles of COVID-19 Outbreak in Tokyo: An Analysis of the Primary Care Clinic-Based Point-of-Care Antibody Testing. *J Prim Care Community Health*. 2020 Dec; 11:2150132720942695. <https://doi.org/10.1177/2150132720942695> PMID: 32674696
82. Tess BH, Granato CFH, Alves MCGP, Pintao MC, Rizzatti E, Nunes MC, et al. SARS-CoV-2 seroprevalence in the municipality of São Paulo, Brazil, ten weeks after the first reported case [Internet]. 2020 Jun [cited 2022 Jan 14] p. 2020.06.29.20142331. Available from: <https://www.medrxiv.org/content/10.1101/2020.06.29.20142331v1>.
83. Velumani A, Nikam C, Suraweera W, Fu SH, Gelband H, Brown P, et al. SARS-CoV-2 Seroprevalence in 12 Cities of India from July–December 2020 [Internet]. 2021 Mar [cited 2022 Jan 20] p. 2021.03.19.21253429. Available from: <https://www.medrxiv.org/content/10.1101/2021.03.19.21253429v1>.
84. Vodičar PM, Valenčak AO, Zupan B, Županc TA, Kurdiija S, Korva M, et al. Low prevalence of active COVID-19 in Slovenia: a nationwide population study of a probability-based sample. *Clin Microbiol Infect*. 2020 Nov 1; 26(11):1514–9. <https://doi.org/10.1016/j.cmi.2020.07.013> PMID: 32688068

85. Wang X, Gao W, Cui S, Zhang Y, Zheng K, Ke J, et al. A population-based seroprevalence survey of severe acute respiratory syndrome coronavirus 2 infection in Beijing, China [Internet]. medRxiv; 2020 [cited 2022 Feb 9], p. 2020.09.23.20197756. Available from: <https://www.medrxiv.org/content/10.1101/2020.09.23.20197756v1>.
86. Ward H, Cooke G, Atchison C, Whitaker M, Elliott J, Moshe M, et al. Declining prevalence of antibody positivity to SARS-CoV-2: a community study of 365,000 adults [Internet]. 2020 Oct [cited 2022 Jan 20] p. 2020.10.26.20219725. Available from: <https://www.medrxiv.org/content/10.1101/2020.10.26.20219725v1>.
87. Ward H, Atchison C, Whitaker M, Ainslie KE, Elliott J, Okell L, et al. Antibody prevalence for SARS-CoV-2 following the peak of the pandemic in England: REACT2 study in 100,000 adults [Internet]. 2020 Aug [cited 2022 Jan 20] p. 2020.08.12.20173690. Available from: <https://www.medrxiv.org/content/10.1101/2020.08.12.20173690v2>.
88. Waterfield T, Watson C, Moore R, Ferris K, Tonry C, Watt AP, et al. Seroprevalence of SARS-CoV-2 antibodies in children—A prospective multicentre cohort study [Internet]. 2020 Sep [cited 2022 Jan 20] p. 2020.08.31.20183095. Available from: <https://www.medrxiv.org/content/10.1101/2020.08.31.20183095v1>.
89. Weis S, Scherag A, Baier M, Kiehntopf M, Kamradt T, Kolanos S, et al. Seroprevalence of SARS-CoV-2 antibodies in an entirely PCR-sampled and quarantined community after a COVID-19 outbreak—the CoNAN study [Internet]. 2020 Jul [cited 2022 Jan 20] p. 2020.07.15.20154112. Available from: <https://www.medrxiv.org/content/10.1101/2020.07.15.20154112v1>.
90. Wells PM, Doores KJ, Couvreur S, Nunez RM, Seow J, Graham C, et al. Estimates of the rate of infection and asymptomatic COVID-19 disease in a population sample from SE England [Internet]. 2020 Jul [cited 2022 Jan 14] p. 2020.07.29.20162701. Available from: <https://www.medrxiv.org/content/10.1101/2020.07.29.20162701v1>.
91. Bendavid E, Mulaney B, Sood N, Shah S, Bromley-Dulfano R, Lai C, et al. COVID-19 antibody seroprevalence in Santa Clara County, California. *Int J Epidemiol*. 2021 Feb 22.
92. Buss LF, Prete CA, Abraham CM, Mendrone A, Salomon T, Almeida-Neto C de, et al. COVID-19 herd immunity in the Brazilian Amazon [Internet]. medRxiv; 2020 [cited 2022 Feb 9]. p. 2020.09.16.20194787. Available from: <https://www.medrxiv.org/content/10.1101/2020.09.16.20194787v1>.
93. Chang L, Hou W, Zhao L, Zhang Y, Wang Y, Wu L, et al. The prevalence of antibodies to SARS-CoV-2 among blood donors in China [Internet]. 2020 Jul [cited 2022 Jan 20] p. 2020.07.13.20153106. Available from: <https://www.medrxiv.org/content/10.1101/2020.07.13.20153106v1>.
94. Davis G, York AJ, Bacon WC, Suh-Chin L, McNeal MM, Yarawsky AE, et al. Seroprevalence of SARS-CoV-2 Infection in Cincinnati Ohio USA from August to December 2020 [Internet]. 2021 Mar [cited 2022 Jan 20] p. 2021.03.11.21253263. Available from: <https://www.medrxiv.org/content/10.1101/2021.03.11.21253263v1>.
95. Gallian P, Pastorino B, Morel P, Chiaroni J, Ninove L, de Lamballerie X. Lower prevalence of antibodies neutralizing SARS-CoV-2 in group O French blood donors. *Antiviral Res*. 2020 Sep; 181:104880. <https://doi.org/10.1016/j.antiviral.2020.104880> PMID: 32679056
96. Germain N, Herwegh S, Hatzfeld AS, Bocket L, Prévost B, Danzé PM, et al. Retrospective study of COVID-19 seroprevalence among tissue donors at the onset of the outbreak before implementation of strict lockdown measures in France. *Cell Tissue Bank*. 2021 Feb 1. <https://doi.org/10.1007/s10561-021-09901-3> PMID: 33523333
97. Jin DK, Nesbitt DJ, Yang J, Chen H, Horowitz J, Jones M, et al. Seroprevalence of anti-SARS-CoV-2 antibodies in a cohort of New York City metro blood donors using multiple SARS-CoV-2 serological assays: Implications for controlling the epidemic and 'Reopening'. *PLoS One*. 2021; 16(4):e0250319.
98. Kamath K, Baum-Jones E, Jordan G, Haynes W, Waitz R, Shon J, et al. Prevalence of antibodies to SARS-CoV-2 in healthy blood donors in New York [Internet]. 2020 Oct [cited 2022 Jan 20] p. 2020.10.19.20215368. Available from: <https://www.medrxiv.org/content/10.1101/2020.10.19.20215368v1>.
99. Martínez-Acuña N, Avalos-Nolazco D, Rodríguez-Rodríguez D, Martínez-Liu C, Taméz RC, Flores-Arechiga A, et al. Seroprevalence of anti-SARS-CoV-2 antibodies in blood donors from Nuevo Leon state, Mexico, during the beginning of the COVID-19 pandemic [Internet]. 2020 Nov [cited 2022 Jan 20] p. 2020.11.28.20240325. Available from: <https://www.medrxiv.org/content/10.1101/2020.11.28.20240325v1>.
100. Ng DL, Goldgof GM, Shy BR, Levine AG, Balcerek J, Bapat SP, et al. SARS-CoV-2 seroprevalence and neutralizing activity in donor and patient blood from the San Francisco Bay Area [Internet]. 2020 May [cited 2022 Jan 20] p. 2020.05.19.20107482. Available from: <https://www.medrxiv.org/content/10.1101/2020.05.19.20107482v2>.

101. Ojal J, Brand SPC, Were V, Okiro EA, Kombe IK, Mburu C, et al. Revealing the extent of the COVID-19 pandemic in Kenya based on serological and PCR-test data [Internet]. medRxiv; 2020 [cited 2022 Feb 9]. p. 2020.09.02.20186817. Available from: <https://www.medrxiv.org/content/10.1101/2020.09.02.20186817v1>.
102. Percivalle E, Cambiè G, Cassaniti I, Nepita EV, Maserati R, Ferrari A, et al. Prevalence of SARS-CoV-2 specific neutralising antibodies in blood donors from the Lodi Red Zone in Lombardy, Italy, as at 06 April 2020. *Euro Surveill Bull Eur Sur Mal Transm Eur Commun Dis Bull*. 2020 Jun; 25(24). <https://doi.org/10.2807/1560-7917.ES.2020.25.24.2001031> PMID: 32583766
103. Slot E, Hogema BM, Reusken CBEM, Reimerink JH, Molier M, Karregat JHM, et al. Herd immunity is not a realistic exit strategy during a COVID-19 outbreak [Internet]. 2022 [cited 2022 Jan 13]. Available from: <https://www.researchsquare.com/article/rs-25862/v1>.
104. Sykes W, Mhlanga L, Swanevelder R, Glatt TN, Grebe E, Coleman C, et al. Prevalence of anti-SARS-CoV-2 antibodies among blood donors in Northern Cape, KwaZulu-Natal, Eastern Cape, and Free State provinces of South Africa in January 2021. *Res Sq*. 2021 Feb 12. <https://doi.org/10.21203/rs.3.rs-233375/v1> PMID: 33594353
105. Thompson CP, Grayson NE, Paton RS, Bolton JS, Lourenço J, Penman BS, et al. Detection of neutralising antibodies to SARS-CoV-2 to determine population exposure in Scottish blood donors between March and May 2020. *Euro Surveill Bull Eur Sur Mal Transm Eur Commun Dis Bull*. 2020 Oct; 25(42). <https://doi.org/10.2807/1560-7917.ES.2020.25.42.2000685> PMID: 33094713
106. Uyoga S, Adetifa IMO, Karanja HK, Nyagwange J, Tuju J, Wanjiku P, et al. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Kenyan blood donors [Internet]. 2020 Jul [cited 2022 Jan 14] p. 2020.07.27.20162693. Available from: <https://www.medrxiv.org/content/10.1101/2020.07.27.20162693v1>.
107. Younas A, Waheed S, Khawaja S, Imam M, Borhany M, Shamsi T. Seroprevalence of SARS-CoV-2 antibodies among healthy blood donors in Karachi, Pakistan. *Transfus Apher Sci Off J World Apher Assoc Off J Eur Soc Haemapheresis*. 2020 Dec; 59(6):102923. <https://doi.org/10.1016/j.transci.2020.102923> PMID: 32868226
108. Vu SL, Jones G, Anna F, Rose T, Richard JB, Bernard-Stoecklin S, et al. Prevalence of SARS-CoV-2 antibodies in France: results from nationwide serological surveillance [Internet]. 2020 Oct [cited 2022 Jan 20] p. 2020.10.20.20213116. Available from: <https://www.medrxiv.org/content/10.1101/2020.10.20.20213116v1>.
109. Cerino P, Coppola A, Volzone P, Pizzolante A, Pierri B, Atripaldi L, et al. Seroprevalence of SARS-CoV-2-specific antibodies in the town of Ariano Irpino (Avellino, Campania, Italy): a population-based study. *Future Sci OA*. 2021 Jan 12; 7(4):FSO673. <https://doi.org/10.2144/fsoa-2020-0203> PMID: 33815819
110. Stout RL, Rigatti SJ. The Silent Pandemic COVID-19 in the Asymptomatic Population [Internet]. 2021 Jan [cited 2022 Jan 20] p. 2020.11.10.20215145. Available from: <https://www.medrxiv.org/content/10.1101/2020.11.10.20215145v3>.
111. Dopico XC, Muschiol S, Christian M, Hanke L, Sheward DJ, Grinberg NF, et al. Seropositivity in blood donors and pregnant women during the first year of SARS-CoV-2 transmission in Stockholm, Sweden [Internet]. 2021 Apr [cited 2022 Jan 20] p. 2020.12.24.20248821. Available from: <https://www.medrxiv.org/content/10.1101/2020.12.24.20248821v2>.
112. Mahallawi WH, Al-Zalabani AH. The seroprevalence of SARS-CoV-2 IgG antibodies among asymptomatic blood donors in Saudi Arabia. *Saudi J Biol Sci*. 2021 Mar; 28(3):1697–701. <https://doi.org/10.1016/j.sjbs.2020.12.009> PMID: 33519277
113. Sughayer MA, Mansour A, Nuirat AA, Souan L, Ghanem M, Siag M, et al. Dramatic Rise of Seroprevalence Rates of SARS-CoV-2 Antibodies among Healthy Blood Donors: The evolution of a Pandemic [Internet]. 2021 Mar [cited 2022 Jan 20] p. 2021.03.02.21252448. Available from: <https://www.medrxiv.org/content/10.1101/2021.03.02.21252448v1>.
114. Valenti L, Bergna A, Pelusi S, Facciotti F, Lai A, Tarkowski M, et al. SARS-CoV-2 seroprevalence trends in healthy blood donors during the COVID-19 Milan outbreak [Internet]. 2020 May [cited 2022 Jan 14] p. 2020.05.11.20098442. Available from: <https://www.medrxiv.org/content/10.1101/2020.05.11.20098442v2>.
115. Angulo FJ, Finelli L, Swerdlow DL. Estimation of US SARS-CoV-2 Infections, Symptomatic Infections, Hospitalizations, and Deaths Using Seroprevalence Surveys. *JAMA Netw Open*. 2021 Jan 4; 4(1):e2033706. <https://doi.org/10.1001/jamanetworkopen.2020.33706> PMID: 33399860
116. Carrat F, Lamballerie X deRahib D Blanché H, Lapidus N, Artaud F, et al. Seroprevalence of SARS-CoV-2 among adults in three regions of France following the lockdown and associated risk factors: a multicohort study [Internet]. 2020 Sep [cited 2022 Jan 20] p. 2020.09.16.20195693. Available from: <https://www.medrxiv.org/content/10.1101/2020.09.16.20195693v1>.

117. Coyle PV, Chemaitelly H, Kacem MABH, Molawi NHAA, Kahlout RAE, Gilliani I, et al. SARS-CoV-2 seroprevalence in the urban population of Qatar: An analysis of antibody testing on a sample of 112,941 individuals [Internet]. 2021 Jan [cited 2022 Jan 20] p. 2021.01.05.21249247. Available from: <https://www.medrxiv.org/content/10.1101/2021.01.05.21249247v1>.
118. Hallal PC, Hartwig FP, Horta BL, Silveira MF, Struchiner CJ, Vidaletti LP, et al. SARS-CoV-2 antibody prevalence in Brazil: results from two successive nationwide serological household surveys. *Lancet Glob Health*. 2020 Nov; 8(11):e1390–8. [https://doi.org/10.1016/S2214-109X\(20\)30387-9](https://doi.org/10.1016/S2214-109X(20)30387-9) PMID: 32979314
119. Hozé N, Paireau J, Lapidus N, Tran Kiem C, Salje H, Severi G, et al. Monitoring the proportion of the population infected by SARS-CoV-2 using age-stratified hospitalisation and serological data: a modelling study. *Lancet Public Health*. 2021 Apr 8.
120. Husby A, Corn G, Krause TG. SARS-CoV-2 infection in households with and without young children: Nationwide cohort study [Internet]. 2021 Mar [cited 2022 Jan 20] p. 2021.02.28.21250921. Available from: <https://www.medrxiv.org/content/10.1101/2021.02.28.21250921v1>.
121. Noh J, Danuser G. Estimation of the fraction of COVID-19 infected people in U.S. states and countries worldwide. *PloS One*. 2021; 16(2):e0246772. <https://doi.org/10.1371/journal.pone.0246772> PMID: 33556142
122. Rosenberg ES, Tesoriero JM, Rosenthal EM, Chung R, Barranco MA, Styer LM, et al. Cumulative incidence and diagnosis of SARS-CoV-2 infection in New York. *Ann Epidemiol*. 2020 Aug; 48:23–29.e4. <https://doi.org/10.1016/j.annepidem.2020.06.004> PMID: 32648546
123. Silveira MF, Barros AJD, Horta BL, Pellanda LC, Victora GD, Dellagostin OA, et al. Population-based surveys of antibodies against SARS-CoV-2 in Southern Brazil. *Nat Med*. 2020 Aug; 26(8):1196–9. <https://doi.org/10.1038/s41591-020-0992-3> PMID: 32641783
124. Adetifa IMO, Uyoga S, Gitonga JN, Mugo D, Otiende M, Nyagwange J, et al. Temporal trends of SARS-CoV-2 seroprevalence in transfusion blood donors during the first wave of the COVID-19 epidemic in Kenya [Internet]. 2021 Feb [cited 2022 Jan 20] p. 2021.02.09.21251404. Available from: <https://www.medrxiv.org/content/10.1101/2021.02.09.21251404v1>.
125. Erikstrup C, Hother CE, Pedersen OBV, Mølbak K, Skov RL, Holm DK, et al. Estimation of SARS-CoV-2 infection fatality rate by real-time antibody screening of blood donors [Internet]. medRxiv; 2020 [cited 2022 Feb 9]. p. 2020.04.24.20075291. Available from: <https://www.medrxiv.org/content/10.1101/2020.04.24.20075291v1>.
126. Saeed S, Drews SJ, Pambrun C, Yi QL, Osmond L, O'Brien SF. SARS-CoV-2 seroprevalence among blood donors after the first COVID-19 wave in Canada. *Transfusion (Paris)*. 2021 Mar; 61(3):862–72. <https://doi.org/10.1111/trf.16296> PMID: 33527398
127. Sutton M, Cieslak P, Linder M. Notes from the Field: Seroprevalence Estimates of SARS-CoV-2 Infection in Convenience Sample—Oregon, May 11–June 15, 2020. *MMWR Morb Mortal Wkly Rep*. 2020 Aug 14; 69(32):1100–1. <https://doi.org/10.15585/mmwr.mm6932a4> PMID: 32790658
128. Gidding HF, Machalek DA, Hendry AJ, Quinn HE, Vette K, Beard FH, et al. Seroprevalence of SARS-CoV-2-specific antibodies in Sydney after the first epidemic wave of 2020. *Med J Aust*. 2021 Mar; 214(4):179–85. <https://doi.org/10.5694/mja2.50940> PMID: 33538019
129. Batista KBC, Caseiro MM, Barros CR, Martins LC, Chioro A, Araújo ESA de, et al. COVID-19 Seroprevalence in Baixada Santista Metropolitan Area—Brazil [Internet]. medRxiv; 2020 [cited 2022 Feb 2]. p. 2020.08.28.20184010. Available from: <https://www.medrxiv.org/content/10.1101/2020.08.28.20184010v1>.
130. Feehan AK, Fort D, Garcia-Diaz J, Price-Haywood E, Velasco C, Sapp E, et al. Point prevalence of SARS-CoV-2 and infection fatality rate in Orleans and Jefferson Parish, Louisiana, May 9–15, 2020 [Internet]. 2020 Jun [cited 2022 Jan 14] p. 2020.06.23.20138321. Available from: <https://www.medrxiv.org/content/10.1101/2020.06.23.20138321v1>.
131. Feehan AK, Velasco C, Fort D, Burton JH, Price-Haywood E, Katzmarzyk PT, et al. Racial and workplace disparities in seroprevalence of SARS-CoV-2 in Baton Rouge, Louisiana, July 15–31, 2020 [Internet]. 2020 Sep [cited 2022 Jan 20] p. 2020.08.26.20180968. Available from: <https://www.medrxiv.org/content/10.1101/2020.08.26.20180968v1>.
132. Malani A, Shah D, Kang G, Lobo GN, Shastri J, Mohanan M, et al. Seroprevalence of SARS-CoV-2 in slums and non-slums of Mumbai, India, during June 29–July 19, 2020 [Internet]. 2020 Sep [cited 2022 Jan 14] p. 2020.08.27.20182741. Available from: <https://www.medrxiv.org/content/10.1101/2020.08.27.20182741v1>.
133. Parker DM, Bruckner T, Vieira VM, Medina C, Minin VN, Felgner PL, et al. Epidemiology of the early COVID-19 epidemic in Orange County, California: comparison of predictors of test positivity, mortality, and seropositivity [Internet]. 2021 Jan [cited 2022 Jan 14] p. 2021.01.13.21249507. Available from: <https://www.medrxiv.org/content/10.1101/2021.01.13.21249507v2>

134. Amorim Filho L, Szwarcwald CL, Mateos S de OG, Leon ACMP de, Medronho R de A Veloso VG, et al. Seroprevalence of anti-SARS-CoV-2 among blood donors in Rio de Janeiro, Brazil. *Rev Saude Publica*. 2020; 54:69. <https://doi.org/10.11606/s1518-8787.2020054002643> PMID: 32638883
135. Lastrucci V, Lorini C, Del Riccio M, Gori E, Chiesi F, Sartor G, et al. SARS-CoV-2 Seroprevalence Survey in People Involved in Different Essential Activities during the General Lock-Down Phase in the Province of Prato (Tuscany, Italy). *Vaccines*. 2020 Dec 19; 8(4). <https://doi.org/10.3390/vaccines8040778> PMID: 33352743
136. Snyder T, Ravenhurst J, Cramer EY, Reich NG, Balzer LB, Alfandari D, et al. Serological surveys to estimate cumulative incidence of SARS-CoV-2 infection in adults (Sero-MAss study), Massachusetts, July-August 2020: a mail-based cross-sectional study. *MedRxiv Prepr Serv Health Sci*. 2021 Mar 9;
137. Williamson JC, Wierzba TF, Santacatterina M, Munawar I, Seals AL, Ballard CAP, et al. Analysis of Accumulated SARS-CoV-2 Seroconversion in North Carolina: The COVID-19 Community Research Partnership [Internet]. 2021 Mar [cited 2022 Jan 20] p. 2021.03.11.21253226. Available from: <https://www.medrxiv.org/content/10.1101/2021.03.11.21253226v1>.
138. Vassallo RR, Bravo MD, Dumont LJ, Hazegh K, Kamel H. Seroprevalence of Antibodies to SARS-CoV-2 in US Blood Donors [Internet]. 2020 Sep [cited 2022 Jan 20] p. 2020.09.17.20195131. Available from: <https://www.medrxiv.org/content/10.1101/2020.09.17.20195131v1>.
139. Ghose A, Bhattacharya S, Karthikeyan AS, Kudale A, Monteiro JM, Joshi A, et al. Community prevalence of antibodies to SARS-CoV-2 and correlates of protective immunity in an Indian metropolitan city [Internet]. 2020 Nov [cited 2022 Jan 20] p. 2020.11.17.20228155. Available from: <https://www.medrxiv.org/content/10.1101/2020.11.17.20228155v2>.
140. Figar S, Pagotto V, Luna L, Salto J, Manslau MW, Mistchenko AS, et al. Community-level SARS-CoV-2 Seroprevalence Survey in urban slum dwellers of Buenos Aires City, Argentina: a participatory research [Internet]. 2020 Jul [cited 2022 Jan 20] p. 2020.07.14.20153858. Available from: <https://www.medrxiv.org/content/10.1101/2020.07.14.20153858v2>.
141. Alandijany TA, El-Kafrawy SA, Al-Ghamdi AA, Qashqari FS, Faizo AA, Tolah AM, et al. Lack of Antibodies to SARS-CoV-2 among Blood Donors during COVID-19 Lockdown: A Study from Saudi Arabia. *Healthc Basel Switz*. 2021 Jan 5; 9(1).